<SEC-DOCUMENT>0001104659-22-088699.txt : 20220810
<SEC-HEADER>0001104659-22-088699.hdr.sgml : 20220810
<ACCEPTANCE-DATETIME>20220810172540
ACCESSION NUMBER:		0001104659-22-088699
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20220808
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220810
DATE AS OF CHANGE:		20220810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOPHARMA, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38247
		FILM NUMBER:		221152846

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2222304d3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:AYTU="http://aytubio.com/20220808">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_AYTU_aytubio.com_20220808 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20220808_20220808 -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001385818 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityCentralIndexKey">0001385818</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aytu-20220808.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-08-08to2022-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001385818</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-08</xbrli:startDate>
        <xbrli:endDate>2022-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>



<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20220808__20220808_zHmYEAjOM1R1"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
August 10, 2022 (<span id="xdx_90D_edei--DocumentPeriodEndDate_c20220808__20220808_z6zlvhmOmTVd"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 8, 2022</ix:nonNumeric></span></b><b>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_900_edei--EntityRegistrantName_c20220808__20220808_zqwxhtZtk6H9"><b><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityRegistrantName">AYTU
BIOPHARMA, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 36%"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20220808__20220808_z7IKRvWHdkM2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 31%"><b><span id="xdx_904_edei--EntityFileNumber_c20220808__20220808_z6peOixEZQFe" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityFileNumber">001-38247</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 31%"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20220808__20220808_z2m5OWznRBgd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityTaxIdentificationNumber">47-0883144</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of incorporation)</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressAddressLine1_c20220808__20220808_zfYFj1JzK379"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityAddressAddressLine1">373
Inverness Parkway</ix:nonNumeric></span></b><b>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20220808__20220808_zghVvvG2Peff"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityAddressAddressLine2">Suite 206</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20220808__20220808_zxnxPgJG7n6h"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityAddressCityOrTown">Englewood</ix:nonNumeric>
</span></b><b>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20220808__20220808_zSVE2QydbyY3"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityAddressStateOrProvince">CO</ix:nonNumeric></span></b><b> <span id="xdx_904_edei--EntityAddressPostalZipCode_c20220808__20220808_zbAUXYNloPQ4"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:EntityAddressPostalZipCode">80112</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices, including
Zip Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: (<span id="xdx_90C_edei--CityAreaCode_c20220808__20220808_zqxERQeU4WPa"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:CityAreaCode">720</ix:nonNumeric></span></b><b>) <span id="xdx_908_edei--LocalPhoneNumber_c20220808__20220808_zW0Ie2iwIPlb"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:LocalPhoneNumber">437-6580</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.3in; text-align: left"><span id="xdx_905_edei--WrittenCommunications_c20220808__20220808_zBmssPJEWo87" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.3in; text-align: left"><span id="xdx_902_edei--SolicitingMaterial_c20220808__20220808_zih2ZMkzpNZ4" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.3in; text-align: left"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20220808__20220808_zCaK3S67Sbia" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.3in; text-align: left"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20220808__20220808_z8Zb90QbdByi" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities registered pursuant to Section 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which<br />
    registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><b><span id="xdx_904_edei--Security12bTitle_c20220808__20220808_zRjRd1tbsLz6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></b></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><b><span id="xdx_900_edei--TradingSymbol_c20220808__20220808_zgwZdLbRcjdd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" name="dei:TradingSymbol">AYTU</ix:nonNumeric></span></b></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><b><span id="xdx_90D_edei--SecurityExchangeName_c20220808__20220808_zzTUmOXM31Ba" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    NASDAQ Stock Market LLC</ix:nonNumeric></span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt">Emerging growth company
</span><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20220808__20220808_zSQ52m5kInx7" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-08-08to2022-08-08" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 1.01. Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">On August&#160;9,
2022, Aytu BioPharma,&#160;Inc. (the &#8220;<b><i>Company</i></b>&#8221;) entered into an underwriting agreement (the
&#8220;<b><i>Underwriting Agreement</i></b>&#8221;) with Cantor Fitzgerald &amp; Co. and Canaccord Genuity LLC, as representatives
of the several underwriters named therein (the &#8220;<b><i>Underwriters</i></b>&#8221;), pursuant to which the Company agreed to
issue and sell an aggregate of (i)&#160;21,505,814 shares of its common stock, and, in lieu of common stock to certain investors
that so chose, pre-funded warrants (the &#8220;<b><i>Pre-Funded Warrants</i></b>&#8221;) to purchase 1,750,000 shares of its common
stock, and (ii)&#160;accompanying warrants (the &#8220;<b><i>Common Warrants</i></b>&#8221;) to purchase 23,255,814 shares of the
Company&#8217;s common stock (the &#8220;<b><i>Offering</i></b>&#8221;). The shares of common stock (or Pre-Funded Warrants) and the
accompanying Common Warrants will be issued separately but can only be purchased together in this Offering. The combined public
offering price for each share of common stock and accompanying Common Warrant is $0.43, and the combined offering price for each
Pre-Funded Warrant and accompanying Common Warrant is $0.429, which equals the public offering price per share of the common stock
and accompanying Common Warrant, less the $0.001 per share exercise price of each Pre-Funded Warrant. The Underwriting Agreement
contains customary representations and warranties, conditions to closing, market standoff provisions, termination provisions and
indemnification obligations, including for liabilities under the&#160;Securities Act of 1933, as amended. The Offering is being made
pursuant to the shelf registration statement on&#160;Form&#160;S-3 (File No.&#160;333-259862) that&#160;was filed by the Company
with the Securities and Exchange Commission (&#8220;<b><i>SEC</i></b>&#8221;) and declared effective by the SEC on October&#160;7,
2021, and a related prospectus supplement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The&#160;Pre-Funded&#160;Warrants
are exercisable at any time. A holder of&#160;Pre-Funded&#160;Warrants may not exercise the warrant if the holder, together with its
affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after
giving effect to such exercise. A holder of&#160;Pre-Funded&#160;Warrants may increase or decrease this percentage, but not in
excess of 9.99% by providing at least 61 days&#8217; prior notice to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The&#160;Common&#160;Warrants
are exercisable at any time after the date of issuance for a period of five years from the date such Common Warrants are first exercisable.
The number of shares of common stock issuable upon exercise of the Common Warrants is subject to adjustment in certain circumstances,
including a stock split of, stock dividend on, or a subdivision, combination or recapitalization of the common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Company estimates
that the net proceeds from the Offering will be approximately $9.1 million, after deducting underwriting discounts and commissions
and estimated Offering expenses. The Company intends to use the net proceeds from the Offering, together with its existing cash resources, for advancing the development of its pipeline assets, including for advancing the PREVEnt
Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS), for growth of the Company&#8217;s commercial business,
and for working capital and general corporate purposes. The Company expects the Offering to close on August&#160;11, 2022, subject to
customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">The Underwriting Agreement
is filed as Exhibit&#160;1.1 to this Current Report on Form&#160;8-K,&#160;and the foregoing description of the terms of the Underwriting
Agreement is qualified in its entirety by reference to such exhibit. The form of&#160;Pre-Funded&#160;Warrant is filed as Exhibit&#160;4.1
to this Current Report on Form&#160;8-K,&#160;and the foregoing description of the terms of the&#160;Pre-Funded&#160;Warrants is qualified
in its entirety by reference to such exhibit. The form of&#160;Common Warrant is filed as Exhibit&#160;4.2 to this Current Report on
Form&#160;8-K,&#160;and the foregoing description of the terms of the&#160;Common&#160;Warrants is qualified in its entirety by reference
to such exhibit. A copy of the opinion of Dorsey&#160;&amp; Whitney LLP, relating to the validity of the shares in connection with the
Offering, is filed as Exhibit&#160;5.1 to this Current Report on&#160;Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;8, 2022, the Company issued a press release announcing the launch of the Offering. A copy of the press release is filed as
Exhibit&#160;99.1 to this Current Report on Form&#160;8-K and is incorporated herein by reference</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August&#160;9, 2022, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is filed
as Exhibit&#160;99.2 to this Current Report on Form&#160;8-K and is incorporated herein by reference</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.6pt; width: 10%"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></p></td>
    <td style="padding: 0.25pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.6pt; vertical-align: bottom; width: 89%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    Agreement dated August&#160;9, 2022</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex4-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Pre-Funded Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Common Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Dorsey&#160;&amp; Whitney LLP</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Dorsey&#160;&amp; Whitney LLP (contained in Exhibit&#160;5.1)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Launch
    Press Release</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></a></td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="tm2222304d3_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pricing
    Press Release</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive
    Data File (the cover page&#160;XBRL tags are embedded within the inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AYTU BIOPHARMA, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 10, 2022</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </span></td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark Oki</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Oki</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZi02DLuzSoiJWkVLEbbCjBNtMmaRVj+QtjS3iMDAM/7//hZiIDa1NjQznZZFDiU1ba49Q4BUZ7QWDI9vuUgi3wJtxnrX1w/sDMwoMBmY+TdQlCIO1Nw6rFOQsVkmsFMhFOpNw3Ivoq2dkr6ZC642uQdsKjkwtG/SaX2NCqZ9kqXkNVSdkZ8imkEzlKL9ByUTBgXr9IL47yPNMRJNhIrFh6tpvTec8NbCqsQldbkT/G30AF85JSQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2222304d3_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 420.75pt"><I>Execution</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AYTU BIOPHARMA,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(a Delaware corporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,505,814</FONT>
Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pre-Funded Warrants to Purchase 1,750,000 Shares
of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrants to Purchase 23,255,814 Shares of Common
Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75in">August&nbsp;9, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cantor Fitzgerald&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Canaccord Genuity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As Representatives of the several</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Underwriters listed in <U>Schedule A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">hereto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c/o Cantor Fitzgerald&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">499 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o Canaccord Genuity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">535 Madison Avenue, 2<SUP>nd</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Aytu BioPharma,&nbsp;Inc., a Delaware corporation
(the &ldquo;<B><I>Company</I></B>&rdquo;), confirms its agreement with Cantor Fitzgerald&nbsp;&amp; Co. (&ldquo;<B><I>Cantor</I></B>&rdquo;),
Canaccord Genuity LLC (&ldquo;<B><I>Canaccord</I></B>&rdquo;) and each of the other underwriter(s)&nbsp;named in <U>Schedule A</U> hereto
(collectively, the &ldquo;<B><I>Underwriters</I></B>,&rdquo; which term shall also include any underwriter substituted as provided in
<U>Section&nbsp;10</U> hereof), for whom Cantor and Canaccord are acting as representatives (in such capacity, the &ldquo;<B><I>Representatives</I></B>&rdquo;)
with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of (i)&nbsp;21,505,814
shares of common stock, par value $0.0001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), of the Company (the &ldquo;<B><I>Shares</I></B>&rdquo;),
(ii)&nbsp;pre-funded warrants, substantially in the form of <U>Annex A</U> hereto, to purchase an aggregate of 1,750,000 shares of Common
Stock at an exercise price equal to $0.001 per share (the &ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo;)and (iii)&nbsp;warrants, substantially
in the form of <U>Annex B</U> hereto, to purchase an aggregate of 23,255,814 shares of Common Stock with an exercise price equal to $0.43
per share (the &ldquo;<B><I>Warrants</I></B>&rdquo; and, together with the Shares and the Pre-Funded Warrants, the &ldquo;<B><I>Securities</I></B>&rdquo;).
As used herein, &ldquo;<B><I>Warrant Shares</I></B>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants and
Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has filed with the Securities and Exchange
Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) a shelf registration statement on Form&nbsp;S-3 (No.&nbsp;333-259862) covering
the public offering and sale of certain securities, including the Securities, under the Securities Act of 1933, as amended (the &ldquo;<B><I>1933
Act</I></B>&rdquo;) and the rules&nbsp;and regulations promulgated thereunder (the &ldquo;<B><I>1933 Act Regulations</I></B>&rdquo;).
As used herein &ldquo;Registration Statement,&rdquo; means such registration statement as amended by any post-effective amendments thereto,
including the exhibits and any schedules thereto, the documents incorporated or deemed to be incorporated by reference therein pursuant
to Item 12 of Form&nbsp;S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof pursuant to Rule&nbsp;430B under
the 1933 Act Regulations (the &ldquo;<B><I>Rule&nbsp;430B Information</I></B>&rdquo;). Each preliminary prospectus used in connection
with the offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to
Item 12 of Form&nbsp;S-3 under the 1933 Act, are collectively referred to herein as a &ldquo;<B><I>preliminary prospectus</I></B>.&rdquo;
Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the Securities
in accordance with the provisions of Rule&nbsp;424(b)&nbsp;(&ldquo;<B><I>Rule&nbsp;424(b)</I></B>&rdquo;) of the 1933 Act Regulations.
Any registration statement filed pursuant to Rule&nbsp;462(b)&nbsp;of the 1933 Act Regulations is herein called the &ldquo;<B><I>Rule&nbsp;462(b)&nbsp;Registration
Statement</I></B>&rdquo; and, after such filing, the term &ldquo;<B><I>Registration Statement</I></B>&rdquo; shall include the Rule&nbsp;462(b)&nbsp;Registration
Statement. The final prospectus, in the form first furnished or made available to the Underwriters for use in connection with the offering
of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form&nbsp;S-3
under the 1933 Act, are collectively referred to herein as the &ldquo;<B><I>Prospectus</I></B>.&rdquo; For purposes of this Agreement,
all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or supplement to any of the
foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval
system or any successor system (&ldquo;<B><I>EDGAR</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Applicable Time</I></B>&rdquo; means
8:30 A.M., New York City time, on August&nbsp;9, 2022 or such other time as agreed by the Company and the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>General Disclosure Package</I></B>&rdquo;
means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus
that is distributed to investors prior to the Applicable Time, and the information included on <U>Schedule&nbsp;B-1</U> hereto, all considered
together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Issuer Free Writing Prospectus</I></B>&rdquo;
means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule&nbsp;433 of the 1933 Act Regulations (&ldquo;<B><I>Rule&nbsp;433</I></B>&rdquo;),
including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule&nbsp;405 of the 1933 Act Regulations (&ldquo;<B><I>Rule&nbsp;405</I></B>&rdquo;))
relating to the Securities that is (i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &ldquo;road show that
is a written communication&rdquo; within the meaning of Rule&nbsp;433(d)(8)(i), whether or not required to be filed with the Commission,
or (iii)&nbsp;exempt from filing with the Commission pursuant to Rule&nbsp;433(d)(5)(i)&nbsp;because it contains a description of the
Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with the Commission
or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule&nbsp;433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Issuer General Use Free Writing Prospectus</I></B>&rdquo;
means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors (other than a &ldquo;<I>bona
fide</I> electronic road show,&rdquo; as defined in Rule&nbsp;433), as evidenced by its being specified in <U>Schedule B-2</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Issuer Limited Use Free Writing Prospectus</I></B>&rdquo;
means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All references in this Agreement to financial statements
and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo; (or other references
of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial
statements and schedules and other information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary
prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement
to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the
filing of any document under the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder
(collectively, the &ldquo;<B><I>1934 Act</I></B>&rdquo;), incorporated or deemed to be incorporated by reference in the Registration Statement,
any preliminary prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section&nbsp;1. Representations and Warranties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Representations
and Warranties by the Company</I>.</B> The Company meets the requirements for use of Form&nbsp;S-3 under the 1933 Act, including the requirements
set forth in General Instruction I.B.1. thereof. The Company represents and warrants to each Underwriter as of the date hereof, the Applicable
Time, the Closing Time (as defined below) and any Date of Delivery (as defined below), and agrees with each Underwriter, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Statement and Prospectuses</U>. Each of the Registration Statement and any amendment thereto has been declared effective under the 1933
Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued
under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings
for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge, contemplated. The Company has complied
with each request (if any) from the Commission for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the Registration Statement and any post-effective
amendment thereto, at the time it became effective, complied in all material respects with the requirements of the 1933 Act and the 1933
Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with
the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary
prospectus delivered by the Company to the Underwriters for use in connection with this offering and the Prospectus was or will be identical
to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation
S-T.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The documents incorporated or deemed to be incorporated
by reference in the Registration Statement, any preliminary prospectus and the Prospectus, when they became effective or at the time they
were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the 1934 Act
and the rules&nbsp;and regulations of the Commission under the 1934 Act (the &ldquo;<B><I>1934 Act Regulations</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accurate
Disclosure</U>. Neither the Registration Statement nor any amendment thereto, at its effective time, at the Closing Time or at any Date
of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, neither (A)&nbsp;the
General Disclosure Package nor (B)&nbsp;any individual Issuer Limited Use Free Writing Prospectus, when considered together with the General
Disclosure Package, included an untrue statement of a material fact or omitted to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment
or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing with the Commission pursuant
to Rule&nbsp;424(b), at the Closing Time or at any Date of Delivery, included, includes or will include an untrue statement of a material
fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The documents incorporated or deemed to be incorporated by reference in the Registration Statement,
the General Disclosure Package and the Prospectus, at the time the Registration Statement became effective or when such documents incorporated
by reference were filed with the Commission, as the case may be, when read together with the other information in the Registration Statement,
the General Disclosure Package or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The representations and warranties in this <U>Section&nbsp;1(a)(ii)</U>&nbsp;shall
not apply to statements in or omissions from the Registration Statement (or any amendment thereto), the General Disclosure Package, the
Prospectus (or any amendment or supplement thereto) or any Issuer Free Writing Prospectus made in reliance upon and in conformity with
written information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of
this Agreement, the only information so furnished shall be the statements relating to the concession figures under the heading &ldquo;Underwriting
Commissions and Discounts&rdquo; and statements relating to stabilization under the heading &ldquo;Underwriting-Price Stabilization, Short
Positions and Penalty Bids&rdquo; in each case contained in the Prospectus (collectively, the &ldquo;<B><I>Underwriter Information</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Issuer
Free Writing Prospectuses</U>. No Issuer Free Writing Prospectus conflicts or will conflict with the information contained in the Registration
Statement or the Prospectus, including any document incorporated by reference therein, and any preliminary or other prospectus deemed
to be a part thereof that has not been superseded or modified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Company
Not Ineligible Issuer</U>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest
time thereafter that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;of
the 1933 Act Regulations) of the Securities and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo;
as defined in Rule&nbsp;405, without taking account of any determination by the Commission pursuant to Rule&nbsp;405 that it is not necessary
that the Company be considered an ineligible issuer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Accountants</U>. Plante&nbsp;&amp; Moran, PLLC, who certified the financial statements and supporting schedules incorporated by reference
in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the
1933 Act, the 1933 Act Regulations and the Public Company Accounting Oversight Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Financial
Statements; Non-GAAP Financial Measures</U>. The financial statements included in the Registration Statement, the General Disclosure Package
and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of
the Company at the dates indicated and its results of operations, stockholders&rsquo; equity and cash flows for the periods specified;
said financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&ldquo;<B><I>GAAP</I></B>&rdquo;)
applied on a consistent basis throughout the periods involved (except for any preparation of non-GAAP measures). The supporting schedules,
if any, present fairly in all material respects in accordance with GAAP the information required to be stated therein. The selected financial
data and the summary financial information included or incorporated by reference in the Registration Statement, the General Disclosure
Package and the Prospectus present fairly the information shown therein and have been compiled on a basis consistent with that of the
audited financial statements included or incorporated by reference therein. Except as included therein, no historical or <I>pro forma</I>
financial statements or supporting schedules are required to be included in the Registration Statement, the General Disclosure Package
or the Prospectus under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the Registration Statement, the General
Disclosure Package or the Prospectus regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules&nbsp;and
regulations of the Commission) comply with Regulation G of the 1934 Act, and Item 10 of Regulation S-K of the 1933 Act, to the extent
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Material Adverse Change in Business</U>. Except as otherwise stated therein, since the respective dates as of which information is given
in the Registration Statement, the General Disclosure Package or the Prospectus, (A)&nbsp;there has been no material adverse change in
the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company, whether or not arising
in the ordinary course of business (a &ldquo;<B><I>Material Adverse Effect</I></B>&rdquo;), (B)&nbsp;there have been no transactions entered
into by the Company, other than those in the ordinary course of business, which are material to the Company, and (C)&nbsp;there has been
no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Good
Standing of the Company</U>. The Company is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware. The Company has requisite corporate power and authority to own, lease and operate its properties and to conduct its
business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its
obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing
in each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct
of business, except where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries</U>.
The Company&rsquo;s only significant subsidiaries (as such term is defined in Rule&nbsp;1-02 of Regulation S-X promulgated by the Commission).
Except as set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly, all of the equity interests
of the Subsidiaries free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction, and
all the equity interests of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and similar rights.
No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution
on such Subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from
transferring any of such Subsidiary&rsquo;s property or assets to the Company or any other Subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and nonassessable and, other
than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights, rights of first refusal or
similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration Statement and the
Prospectus as of the dates referred to therein (other than the grant of additional equity securities under the Company&rsquo;s existing
equity incentive plans, or changes in the number of outstanding shares of Common Stock of the Company due to the issuance of shares upon
the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof or equity securities
issuable upon the achievement of certain milestones under the Company&rsquo;s outstanding contingent value rights or issuable under the
achievement of certain milestones related to assets acquired from Rumpus Therapeutics) and such authorized capital stock conforms to the
description thereof set forth in the Registration Statement and the Prospectus. The description of the securities of the Company in the
Registration Statement and the Prospectus is complete and accurate in all material respects. Except as disclosed in or contemplated by
the Registration Statement or the Prospectus, as of the date referred to therein, the Company does not have outstanding any options to
purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into, or exchangeable for, or any contracts
or commitments to issue or sell, any shares of capital stock or other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Options</U>. With respect to the outstanding stock options (the &ldquo;<B><I>Stock Options</I></B>&rdquo;) granted pursuant to the stock-based
compensation plans of the Company (the &ldquo;<B><I>Company Stock Plans</I></B>&rdquo;), (i)&nbsp;each Stock Option intended to qualify
as an &ldquo;incentive stock option&rdquo; under Section&nbsp;422 of the Internal Revenue Code of 1986 , as amended (the &ldquo;<B><I>Code</I></B>&rdquo;),
so qualified, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option
was by its terms to be effective (the &ldquo;<B><I>Grant Date</I></B>&rdquo;) by all necessary corporate action, including, as applicable,
approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder
approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed
and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans and all
other applicable laws and regulatory rules&nbsp;or requirements, except where the failure to comply with such laws, regulatory rules&nbsp;or
requirements would not result in a Material Adverse Effect, and (iv)&nbsp;each such grant was properly accounted for in accordance with
GAAP in the financial statements (including the related notes) of the Company included in the Registration Statement, the General Disclosure
Package and the Prospectus, to the extent required under GAAP to be accounted for in such financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization
of Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization
and Description of Securities</U>. The Securities to be purchased by the Underwriters from the Company have been duly authorized for issuance
and sale to the Underwriters pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against
payment of the consideration set forth herein, will be validly issued and fully paid and non-assessable; and the issuance of the Securities
is not subject to the preemptive or other similar rights of any securityholder of the Company. The Common Stock, Pre-Funded Warrants and
the Warrants conform in all material respects to all statements relating thereto contained in the Registration Statement, the General
Disclosure Package and the Prospectus. Each of the Warrants and Pre-Funded Warrants have been duly authorized by the Company and, when
executed and delivered by the Company, will be valid and binding agreements of the Company, enforceable against the Company in accordance
with their respective terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or
other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The Warrant Shares
have been duly authorized and validly reserved for issuance upon exercise of the Warrants or the Pre-Funded Warrants in a number sufficient
to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Warrants or the Pre-Funded
Warrants, in accordance therewith against payment of the exercise price as provided therein, will be validly issued, fully paid and nonassessable,
and the issuance of the Warrant Shares is not subject to any preemptive or similar rights. No holder of Securities will be subject to
personal liability solely by reason of being such a holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Rights</U>. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant
to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other
than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and have been
waived or satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Violations, Defaults and Conflicts</U>. The Company is not (A)&nbsp;in violation of its charter or by-laws, (B)&nbsp;in default in
the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed
of trust, loan or credit agreement, note, lease or other agreement or instrument to which the Company is a party or by which it may be
bound or to which any of the properties or assets of the Company is subject (collectively, &ldquo;<B><I>Agreements and Instruments</I></B>&rdquo;),
except for such defaults that would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect, or
(C)&nbsp;in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body,
regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of its properties,
assets or operations (each, a &ldquo;<B><I>Governmental Entity</I></B>&rdquo;), except for such violations that would not reasonably be
expected to, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of this Agreement
and the consummation of the transactions contemplated herein and in the Registration Statement, the General Disclosure Package and the
Prospectus (including the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as described
therein under the caption &ldquo;Use of Proceeds&rdquo;) and compliance by the Company with its obligations hereunder have been duly authorized
by all necessary corporate action and do not and will not, whether with or without the giving of notice or passage of time or both, conflict
with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any
lien, charge or encumbrance upon any properties or assets of the Company pursuant to, the Agreements and Instruments (except for such
conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not reasonably be expected to, singly or
in the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of (i)&nbsp;the provisions of the
charter or by-laws of the Company or (ii)&nbsp;any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental
Entity, except with respect to clause (ii), such violations as would not reasonably be expected to, singly or in the aggregate, result
in a Material Adverse Effect. As used herein, a &ldquo;<B><I>Repayment Event</I></B>&rdquo; means any event or condition which gives the
holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&rsquo;s behalf) the right to require
the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Labor Dispute</U>. No labor dispute with the employees of the Company exists or, to the knowledge of the Company, is imminent, and
the Company has no knowledge of any existing or imminent labor dispute by the employees of any of its principal suppliers, manufacturers,
customers or contractors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Proceedings</U>. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no
action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the
Company, threatened against the Company, which would reasonably be expected to, singly or in the aggregate, result in a Material Adverse
Effect, or which would reasonably be expected to, singly or in the aggregate, materially and adversely affect the consummation of the
transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accuracy
of Exhibits</U>. There are no contracts or documents which are required to be described in the Registration Statement, the General Disclosure
Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been so described and filed as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Further Requirements</U>. No filing with, or authorization, approval, consent, license, order, registration, qualification or decree
of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder, in connection with
the offering, issuance or sale of the Securities hereunder or the consummation of the transactions contemplated by this Agreement, except
such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules&nbsp;of the Nasdaq Stock
Market LLC, state securities laws or the rules&nbsp;of the Financial Industry Regulatory Authority,&nbsp;Inc. (&ldquo;<B><I>FINRA</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Possession
of Licenses and Permits</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries have
made all filings, applications and submissions required by, possesses and is operating in compliance with, all approvals, licenses, certificates,
certifications, clearances, consents, grants, exemptions, marks, notifications, orders, permits and other authorizations issued by, the
appropriate federal, state or foreign Governmental Authority (including, without limitation, the United States Food and Drug Administration
(the &ldquo;<B><I>FDA</I></B>&rdquo;), the United States Drug Enforcement Administration or any other foreign, federal, state, provincial,
court or local government or regulatory authorities including self-regulatory organizations engaged in the regulation of clinical trials,
pharmaceuticals, biologics or biohazardous substances or materials) necessary for the ownership or lease of their respective properties
or to conduct its businesses as described in the Registration Statement and the Prospectus (collectively, &ldquo;<B><I>Permits</I></B>&rdquo;),
except for such Permits the failure of which to possess, obtain or make the same would not have a Material Adverse Effect; the Company
and its Subsidiaries are in compliance with the terms and conditions of all such Permits, except where the failure to be in compliance
would not have a Material Adverse Effect; all of the Permits are valid and in full force and effect, except where any invalidity, individually
or in the aggregate, would not be reasonably expected to have a Material Adverse Effect; and neither the Company nor any of its Subsidiaries
has received any written notice relating to the limitation, revocation, cancellation, suspension, modification or non-renewal of any such
Permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse
Effect, or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course.
To the extent required by applicable laws and regulations of the FDA, the Company or the applicable Subsidiary has submitted to the FDA
an Investigational New Drug Application or amendment or supplement thereto for each clinical trial it has conducted or sponsored or is
conducting or sponsoring; all such submissions were in material compliance with applicable laws and rules&nbsp;and regulations when submitted
and no material deficiencies have been asserted by the FDA with respect to any such submissions. The Company and each Subsidiary possess
such valid and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies
or bodies necessary to conduct their respective businesses, and neither the Company nor any Subsidiary has received, or has any reason
to believe that it will receive, any notice of proceedings relating to the revocation or modification of, or non-compliance with, any
such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding,
could result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U>. The Company and each of its Subsidiaries are in compliance with all applicable laws, regulations and statutes (including
all environmental laws and regulations) in the jurisdictions in which it carries on business; the Company has not received a notice of
non-compliance, nor knows of, nor has reasonable grounds to know of, any facts that could give rise to a notice of non-compliance with
any such laws, regulations and statutes, and is not aware of any pending change or contemplated change to any applicable law or regulation
or governmental position; in each case that would materially adversely affect the business of the Company or the business or legal environment
under which the Company operates. Each of the Company and its Subsidiaries: (A)&nbsp;is and at all times has been in compliance with all
statutes, rules, or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by
the Company or its Subsidiaries (&ldquo;<B><I>Applicable Laws</I></B>&rdquo;), except as could not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse Effect; (B)&nbsp;has not received any FDA Form&nbsp;483, notice of adverse finding,
warning letter, untitled letter or other correspondence or notice from the FDA or any other Governmental Authority alleging or asserting
noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or
amendments thereto required by any such Applicable Laws (&ldquo;<B><I>Authorizations</I></B>&rdquo;); (C)&nbsp;possesses all material
Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such
Authorizations; (D)&nbsp;has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action from any Governmental Authority or third party alleging that any product operation or activity is in violation of any
Applicable Laws or Authorizations and has no knowledge that any such Governmental Authority or third party is considering any such claim,
litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;has not received notice that any Governmental Authority has
taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental
Authority is considering such action; (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that
all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and
correct on the date filed (or were corrected or supplemented by a subsequent submission); and (G)&nbsp;other than those that have not
been subsequently withdrawn has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted
or issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, &ldquo;dear healthcare provider&rdquo; letter,
or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation
and, to the Company&rsquo;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Clinical
Studies</U>. The preclinical studies and tests and clinical trials described in the Prospectus were, and, if still pending, are being
conducted in all material respects in accordance with the experimental protocols, procedures and controls pursuant to, where applicable,
accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company;
the descriptions of such studies, tests and trials, and the results thereof, contained in the Prospectus are accurate and complete in
all material respects; the Company is not aware of any tests, studies or trials not described in the Prospectus, the results of which
reasonably call into question the results of the tests, studies and trials described in the Prospectus; and the Company has not received
any written notice or correspondence from the FDA or any foreign, state or local Governmental Authority exercising comparable authority
or any institutional review board or comparable authority requiring the termination, suspension, clinical hold or material modification
of any tests, studies or trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fraud
and Abuse</U>. The Company is not the subject of any pending or, to the knowledge of the Company, threatened investigation in respect
of the Company or the Company&rsquo;s products, by the FDA pursuant to its &ldquo;Fraud, Untrue Statements of Material Facts, Bribery,
and Illegal Gratuities&rdquo; Final Policy set forth in 56 Fed. Reg. 46191 (September&nbsp;10, 1991) and any amendments thereto. Neither
the Company nor, to the knowledge of the Company, any of its officers, employees or agents has been convicted of any crime or engaged
in any conduct that could result in a debarment or exclusion (A)&nbsp;under 21 U.S.C. Section&nbsp;335a, or (B)&nbsp;any similar applicable
law. As of the date hereof, except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, no claims,
actions, proceedings or investigations that would reasonably be expected to result in such a debarment or exclusion are pending against
the Company or, to the knowledge of the Company, any of its officers, employees or agent, or, to the knowledge of the Company, threatened
against the Company or any of its officers, employees or agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Title
to Property</U>. The Company has good and marketable title to all real property owned by it and good title or valid leases to all personal
property owned by it, in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances
(except for customary easements and rights of way) of any kind except such as (A)&nbsp;are described in the Registration Statement, the
General Disclosure Package and the Prospectus or (B)&nbsp;do not, singly or in the aggregate, materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of such property by the Company; and all of the leases and subleases
material to the business of the Company and under which the Company holds properties described in the Registration Statement, the General
Disclosure Package or the Prospectus, are in full force and effect, and the Company has not received any written notice of any material
claim of any sort that has been asserted by anyone adverse to the rights of the Company under any of the leases or subleases mentioned
above, or affecting or questioning the rights of the Company to the continued possession of the leased or subleased premises under any
such lease or sublease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Possession
of Intellectual Property</U>. Except as disclosed in the Registration Statement and the Prospectus, the Company and its Subsidiaries own,
possess, license or have other rights to use those foreign and domestic patents, patent applications, trade and service marks, trade and
service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology,&nbsp;Internet domain names, know-how
and other intellectual property (collectively, the &ldquo;<B><I>Intellectual Property</I></B>&rdquo;), necessary for the conduct of their
respective businesses as now conducted except to the extent that the failure to own, possess, license or otherwise hold adequate rights
to use such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect. Except as disclosed in
the Registration Statement and the Prospectus (i)&nbsp;there are no rights of third parties to any Intellectual Property or licenses;
(ii)&nbsp;to the Company&rsquo;s knowledge, there is no infringement by third parties of any Intellectual Property that is owned by the
Company and its Subsidiaries; (iii)&nbsp;there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding
or claim by others challenging the Company&rsquo;s and its Subsidiaries&rsquo; rights in or to any Intellectual Property, and the Company
is unaware of any facts which could form a reasonable basis for any such action, suit, proceeding or claim; (iv)&nbsp;there is no pending
or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any
Intellectual Property; (v)&nbsp;there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim
by others that the Company and its Subsidiaries infringe or otherwise violate any Intellectual Property rights of others; (vi)&nbsp;to
the Company&rsquo;s knowledge, there is no third-party U.S. patent or published U.S. patent application which contains claims for which
an Interference Proceeding (as defined in 35 U.S.C. &sect; 135) has been commenced against any patent or patent application described
in the Prospectus as being owned by or licensed to the Company; and (vii)&nbsp;the Company and its Subsidiaries have complied with the
terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or such Subsidiary, and all such agreements
are in full force and effect, except, in the case of any of clauses (i)-(vii)&nbsp;above, for any such infringement by third parties or
any such pending or threatened suit, action, proceeding or claim as would not, individually or in the aggregate, result in a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or would not reasonably
be expected to, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;the Company is not in violation of any federal,
state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative
interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection
of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata)
or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively,
 &ldquo;<B><I>Hazardous Materials</I></B>&rdquo;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials (collectively, &ldquo;<B><I>Environmental Laws</I></B>&rdquo;), (B)&nbsp;the Company has all permits,
authorizations and approvals required under any applicable Environmental Laws and is in compliance with their requirements, (C)&nbsp;there
are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand
letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against
the Company and (D)&nbsp;to the knowledge of the Company, there are no existing events, conditions or facts that would reasonably be expected
to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity,
against or affecting the Company relating to Hazardous Materials or any Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Controls</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company maintains
an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that
complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the
Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the Commission&rsquo;s rules&nbsp;and forms, including controls and procedures designed to ensure that such information is
accumulated and communicated to the Company&rsquo;s management as appropriate to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxviii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accounting
Controls</U>. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, the Company maintains
effective internal control over financial reporting (as defined under Rule&nbsp;13a-15 and 15d-15 of the 1934 Act Regulations) and a system
of internal accounting controls sufficient to provide reasonable assurances that (A)&nbsp;transactions are executed in accordance with
management&rsquo;s general or specific authorization; (B)&nbsp;transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted only in accordance
with management&rsquo;s general or specific authorization; (D)&nbsp;the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences and (E)&nbsp;the interactive data in eXtensible
Business Reporting Language incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus
fairly presents the information called for in all material respects and is prepared in accordance with the Commission&rsquo;s rules&nbsp;and
guidelines applicable thereto. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, since
the end of the Company&rsquo;s most recent audited fiscal year, there has been (1)&nbsp;no material weakness in the Company&rsquo;s internal
control over financial reporting (whether or not remediated) and (2)&nbsp;no change in the Company&rsquo;s internal control over financial
reporting that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial
reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Payment
of Taxes</U>. All United States federal income tax returns of the Company required by law to be filed have been filed and all taxes shown
by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or
will be promptly taken and as to which adequate reserves have been provided other than as would not reasonably be expected to, singly
or in the aggregate, have a Material Adverse Effect. The Company has filed all other tax returns that are required to have been filed
by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not result
in a Material Adverse Effect, and has paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company,
except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company,
other than as would not reasonably be expected to, singly or in the aggregate, have a Material Adverse Effect. Except as disclosed in
the Registration Statement, the General Disclosure Package and the Prospectus, the charges, accruals and reserves on the books of the
Company in respect of any income and corporation tax liability for any years not finally determined are believed to be adequate to meet
any assessments or re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy
that would not reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxx)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance</U>.
The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks as is reasonably prudent and customary
in the businesses in which it is engaged, and all such insurance is in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any of its Subsidiaries
will be or become, at any time prior to the termination of this Agreement, required to register as an &ldquo;investment company,&rdquo;
as such term is defined in the Investment Company Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Manipulation</U>. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly
or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes, the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Integration</U>. The Company has not sold or issued any securities that would be integrated with the offering of the Common Stock contemplated
by this Agreement pursuant to the Securities Act, the rules&nbsp;and regulations thereunder or the interpretations thereof by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>ERISA.</U>
To the knowledge of the Company, each material employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement
Income Security Act of 1974, as amended (&ldquo;<B><I>ERISA</I></B>&rdquo;), that is maintained, administered or contributed to by the
Company or any of its affiliates for employees or former employees of the Company and any of its Subsidiaries has been maintained in material
compliance with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including but not limited
to ERISA and the Code; no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has
occurred which would result in a material liability to the Company with respect to any such plan excluding transactions effected pursuant
to a statutory or administrative exemption; and for each such plan that is subject to the funding rules&nbsp;of Section&nbsp;412 of the
Code or Section&nbsp;302 of ERISA, no &ldquo;accumulated funding deficiency&rdquo; as defined in Section&nbsp;412 of the Code has been
incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid
contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Foreign
Corrupt Practices Act</U>. (i)&nbsp;Neither the Company nor the Subsidiaries, nor any director, officer, or employee of the Company or
any Subsidiary nor, to the Company&rsquo;s knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary
has, in the past five years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any
contribution in violation of applicable law) or made any contribution or other payment to any official of, or candidate for, any federal,
state, municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any applicable law
or of the character required to be disclosed in the Prospectus; (ii)&nbsp;no relationship, direct or indirect, exists between or among
the Company or any Subsidiary or any affiliate of any of them, on the one hand, and the directors, officers and stockholders of the Company
or any Subsidiary, on the other hand, that is required by the Securities Act to be described in the Registration Statement and the Prospectus
that is not so described; (iii)&nbsp;no relationship, direct or indirect, exists between or among the Company or any Subsidiary or any
affiliate of them, on the one hand, and the directors, officers, or stockholders of the Company or any Subsidiary, on the other hand,
that is required by the rules&nbsp;of FINRA to be described in the Registration Statement and the Prospectus that is not so described;
(iv)&nbsp;except as described in the Registration Statement and the Prospectus, there are no material outstanding loans or advances or
material guarantees of indebtedness by the Company or any Subsidiary to or for the benefit of any of their respective officers or directors
or any of the members of the families of any of them; and (v)&nbsp;the Company has not offered, or caused any placement agent to offer,
Common Stock to any person with the intent to influence unlawfully (A)&nbsp;a customer or supplier of the Company or any Subsidiary to
alter the customer&rsquo;s or supplier&rsquo;s level or type of business with the Company or any Subsidiary or (B)&nbsp;a trade journalist
or publication to write or publish favorable information about the Company or any Subsidiary or any of their respective products or services,
and, (vi)&nbsp;neither the Company nor any Subsidiary nor any director, officer or employee of the Company or any Subsidiary nor, to the
Company&rsquo;s knowledge, any agent, affiliate or other person acting on behalf of the Company or any Subsidiary has (A)&nbsp;violated
or is in violation of any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any other applicable
anti-bribery or anti-corruption law (collectively, &ldquo;<B><I>Anti-Corruption Laws</I></B>&rdquo;), (B)&nbsp;promised, offered, provided,
attempted to provide or authorized the provision of anything of value, directly or indirectly, to any person for the purpose of obtaining
or retaining business, influencing any act or decision of the recipient, or securing any improper advantage; or (C)&nbsp;made any payment
of funds of the Company or any Subsidiary or received or retained any funds in violation of Anti-Corruption Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Money
Laundering Laws</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions to which the Company or its Subsidiaries are subject, the rules&nbsp;and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Authority (collectively,
the &ldquo;<B><I>Money Laundering Laws</I></B>&rdquo;); and no action, suit or proceeding by or before any Governmental Authority involving
the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>OFAC</U>.
i) The Company represents that, neither the Company nor any of its Subsidiaries (collectively, the &ldquo;<B><I>Entity</I></B>&rdquo;)
or any director, officer, employee, agent, affiliate or representative of the Entity, is a government, individual, or entity (in this
paragraph (xxxvii), <I>&ldquo;<B>Person</B>&rdquo;</I>) that is, or is owned or controlled by a Person that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">(A)&nbsp;&nbsp;the subject of any sanctions administered
or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;<B><I>OFAC</I></B>&rdquo;), the United
Nations Security Council, the European Union, Her Majesty&rsquo;s Treasury, or other relevant sanctions authorities, including, without
limitation, designation on OFAC&rsquo;s Specially Designated Nationals and Blocked Persons List or OFAC&rsquo;s Foreign Sanctions Evaders
List (as amended, collectively, &ldquo;<B><I>Sanctions</I></B>&rdquo;), nor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">(B)&nbsp;&nbsp;located, organized or resident in a country
or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory (including, without limitation,
Cuba,&nbsp;Iran, North Korea, Sudan, Syria and the Crimea Region of the Ukraine) (the &ldquo;<B><I>Sanctioned Countries</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)&nbsp;&nbsp;The Entity represents and
covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available
such proceeds to any Subsidiary, joint venture partner or other Person:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(A)&nbsp;&nbsp;to fund or facilitate any
activities or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the
subject of Sanctions or is a Sanctioned Country; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">(B)&nbsp;&nbsp;in any other manner that will result in a
violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or
otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">(iii)&nbsp;&nbsp;The Entity represents and covenants that,
except as detailed in the Registration Statement and the Prospectus, for the past 5 years, it has not engaged in, is not now engaging
in, and will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing
or transaction is or was the subject of Sanctions or is or was a Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxviii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Statistical
and Market-Related Data</U>. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package
or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate
in all material respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Accuracy
of Descriptions</U>. The statements set forth in the Registration Statement, the General Disclosure Package and the Prospectus under the
caption &ldquo;Description of Capital Stock,&rdquo; insofar as they purport to constitute a summary of the terms of the Common Stock and
under the caption &ldquo;Material United States Federal Income Tax Consequences to Non-U.S. Holders of Our Common Stock&rdquo; insofar
as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair summaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xl)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Exchange Listing</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act and is listed
on the Nasdaq Capital Market; the Company has taken no action designed to, or likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act or delisting the Common Stock from the Nasdaq Capital Market; the Company has not received
any notice that it is out of compliance with the listing or maintenance requirements of the Nasdaq Capital Market and the Company is,
and will continue to be, in material compliance with all such listing and maintenance requirements; and the Company has not received any
notification that the Commission or the Nasdaq Capital Market is contemplating terminating the registration of the Common Stock under
the Exchange Act or delisting the Common Stock from the Nasdaq Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xli)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Related
Party Transactions</U>. There are no business relationships or related-party transactions involving the Company or any other person required
to be described in the Registration Statement, any preliminary prospectus, the Prospectus and the General Disclosure Package which have
not been described as required. The General Disclosure Package contains in all material respects the same description of the matters set
forth in the preceding sentence contained in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Brokers</U>.
Except for the underwriting discounts and commissions payable to the Underwriters as described in the Registration Statement, the General
Disclosure Package and the Prospectus, there is no broker, finder or other party that is entitled to receive from the Company any brokerage
or finder&rsquo;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xliii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Stabilization</U>. The Company has not taken, directly or indirectly, any action designed to or that could reasonably be expected to cause
or result in any stabilization or manipulation of the price of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xliv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Margin
Rules</U>. The application of the proceeds received by the Company from the issuance, sale and delivery of the Securities as described
in the Registration Statement, the General Disclosure Package and the Prospectus will not violate Regulation T, U or X of the Board of
Governors of the Federal Reserve System or any other regulation of such Board of Governors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Forward-Looking
Statements</U>. No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act) contained in the Registration
Statement, the General Disclosure Package or the Prospectus has been made or reaffirmed by the Company without a reasonable basis or has
been disclosed by the Company other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sarbanes-Oxley
Act</U>. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&rsquo;s directors
or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules&nbsp;and
regulations promulgated in connection therewith, including Section&nbsp;402 related to loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlvii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>FINRA
Affiliations</U>. There are no affiliations or associations between any member of FINRA and any of the Company&rsquo;s officers, directors
or 5% or greater securityholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlviii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration
Statement for Warrants and Pre-Funded Warrants</U>. The Company shall, at all times while any Warrants or Pre-Funded Warrants are outstanding
and exercisable, use its commercially reasonable efforts to maintain a registration statement covering the issue and sale of the Warrant
Shares upon exercise of the Warrants or the Pre-Funded Warrants such that the Warrant Shares, when issued, will not be subject to resale
restrictions under the Securities Act except to the extent that the Warrant Shares are owned by affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Reserve
for Warrant Shares</U>. The Company shall, at all times while any Warrants or Pre-Funded Warrants are outstanding, reserve and keep available
out of the aggregate of its authorized but unissued or treasury shares available to the Company, and, in each case, otherwise unreserved
Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants or Pre-Funded Warrants, the
number of Warrant Shares that are initially issuable and deliverable upon the then-outstanding Warrants or Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cybersecurity</U>.
The Company and its Subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B><I>IT Systems</I></B>&rdquo;) are adequate for, and operate and perform
in all material respects as required in connection with the operation of the business of the Company as currently conducted, free and
clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its Subsidiaries
have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data, including all &ldquo;<B><I>Personal Data</I></B>&rdquo; (defined below) and all sensitive, confidential or regulated
data (&ldquo;<B><I>Confidential Data</I></B>&rdquo;) used in connection with their businesses. &ldquo;<B><I>Personal Data</I></B>&rdquo;
means (i)&nbsp;a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number or
tax identification number, driver&rsquo;s license number, passport number, credit card number, bank information, or customer or account
number; (ii)&nbsp;any information which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission
Act, as amended; (iii)&nbsp;&ldquo;personal data&rdquo; as defined by the European Union General Data Protection Regulation (&ldquo;<B><I>GDPR</I></B>&rdquo;)
(EU 2016/679); (iv)&nbsp;any information which would qualify as &ldquo;protected health information&rdquo; under the Health Insurance
Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively,
 &ldquo;<B><I>HIPAA</I></B>&rdquo;); (v)&nbsp;any &ldquo;personal information&rdquo; as defined by the California Consumer Privacy Act
(&ldquo;<B><I>CCPA</I></B>&rdquo;); and (vi)&nbsp;any other piece of information that allows the identification of such natural person,
or his or her family, or permits the collection or analysis of any data related to an identified person&rsquo;s health or sexual orientation.
There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied
without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating
to the same. The Company and its Subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments,
orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual
obligations relating to the privacy and security of IT Systems, Confidential Data, and Personal Data and to the protection of such IT
Systems, Confidential Data, and Personal Data from unauthorized use, access, misappropriation or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(li)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Data Privacy Laws</U>. The Company and its Subsidiaries are, and at all prior times were, in material compliance with all applicable
state and federal data privacy and security laws and regulations, including without limitation HIPAA, CCPA, and the GDPR (collectively,
the &ldquo;<B><I>Privacy Laws</I></B>&rdquo;). To ensure compliance with the Privacy Laws, the Company has in place, complies with, and
takes appropriate steps to ensure compliance in all material respects with their policies and procedures relating to data privacy and
security and the collection, storage, use, processing, disclosure, handling, and analysis of Personal Data and Confidential Data (the
 &ldquo;<B><I>Policies</I></B>&rdquo;). The Company has at all times made all disclosures to users or customers required by applicable
laws and regulatory rules&nbsp;or requirements, and none of such disclosures made or contained in any Policy have been inaccurate or in
violation of any applicable laws and regulatory rules&nbsp;or requirements in any material respect. The Company further certifies that
neither it nor any Subsidiary: (i)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential
violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any
such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective
action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposes any obligation or liability
under any Privacy Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Officer&rsquo;s
Certificates</U>. Any certificate signed by any officer of the Company delivered to the Representatives or to counsel for the Underwriters
shall be deemed a representation and warranty by the Company (and not by such officer in his or her personal capacity) to each Underwriter
as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section&nbsp;2. Purchase of the Securities by
the Underwriters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Securities</I></B>.
On the basis of the representations, warranties, and agreements herein contained and subject to the terms and conditions herein set forth,
the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees to
purchase from the Company the number of Shares, Pre-Funded Warrants and Warrants in <U>Schedule A</U> hereto opposite the name of such
Underwriter. The purchase price to be paid by the Underwriter to the Company for the Shares will be $0.40205 per share of Common Stock
and Warrant to purchase one share of Common Stock (or, for the Pre-Funded Warrants in lieu of Shares, 0.40105 per Pre-Funded Warrant and
Warrant to purchase one share of Common Stock) (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Payment</I></B>.
Payment of the purchase price for, and delivery of, the Shares and Warrants shall be made at the offices of Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, or at such other place as shall be agreed upon by the Representatives
and the Company, at 9:00 A.M.&nbsp; (New York City time) on August&nbsp;11, 2022 (unless postponed in accordance with the provisions of
<U>Section&nbsp;10</U> hereof), or such other time not later than ten business days after such date as shall be agreed upon by the Representatives
and the Company (such time and date of payment and delivery being herein called &ldquo;<B><I>Closing Time</I></B>&rdquo;). Delivery of
the Shares and Warrants shall be made through the facilities of The Depository Trust Company (&ldquo;<B><I>DTC</I></B>&rdquo;) unless
the Representatives shall otherwise instruct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Payment shall be made to the Company by wire transfer
of immediately available funds to bank accounts designated by the Company against delivery to the Representatives for the respective accounts
of the Underwriters of the Securities to be purchased by them. It is understood that each Underwriter has authorized the Representatives,
for its account, to accept delivery of, receipt for, and make payment of the Purchase Price for, the Securities, which it has agreed to
purchase. Each of the Representatives, individually and not as representative of the Underwriters, may (but shall not be obligated to)
make payment of the Purchase Price for the Securities to be purchased by any Underwriter whose funds have not been received by the Closing
Time, as the case may be, but such payment shall not relieve such Underwriter from its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Delivery
of the Pre-Funded Warrants</I></B>. Delivery of the Pre-Funded Warrants shall be made by physical delivery to the Representative or the
purchasers of the Pre-Funded Warrants, as directed by the Representatives, in definitive form, registered in such names and in such denominations
as the Representatives shall request in writing not later than the Closing Time. The Pre-Funded Warrants will be made available for inspection
by the Representatives on the business day prior to the Closing Time. Notwithstanding the foregoing, if the Representatives so instruct,
the purchasers of the Pre-Funded Warrants in the offering shall make payment for the Pre-Funded Warrants and accompanying Warrants on
the Closing Time to the Company by wire transfer in immediately available funds to the account specified by the Company at a purchase
price of $0.429 per Pre-Funded Warrant and accompanying Warrant, in lieu of payment by the Underwriters for such Pre-Funded Warrants,
and the Company shall deliver such Pre-Funded Warrants to such purchasers on the Closing Time in definitive form against such payment,
in lieu of the Company&rsquo;s obligation to deliver such Pre-Funded Warrants to the Underwriters; provided that the Underwriters shall
withhold $0.02895 per Pre-Funded Warrant with respect to such Pre-Funded Warrants as an offset against the payment owed by the Underwriters
to the Company with respect to the Securities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the event a purchaser of the Pre-Funded Warrants fails to make payment to the Company for all or part of the Pre-Funded Warrants on the
Closing Time, the Representatives may elect, by written notice to the Company, to receive shares of Common Stock and accompanying Warrants
at a price per Share and accompanying Warrant of $</FONT>0.40205 in lieu of all or a portion of such Pre-Funded Warrants and accompanying
Warrants to be delivered to the Underwriters under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Denominations;
Registration</I></B>. The Securities shall be in such denominations and registered in such names as the Representatives may request in
writing at least one full business day before the Closing Time or the relevant Date of Delivery, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;3.
Covenants of the Company.</B></FONT> The Company covenants with each Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Compliance
with Securities Regulations and Commission Requests</I></B>. The Company, subject to <U>Section&nbsp;3(b)</U>&nbsp;hereof, will comply
with the requirements of Rule&nbsp;430B, and will notify the Representatives promptly, and confirm the notice in writing, (i)&nbsp;when
any post-effective amendment to the Registration Statement shall have been filed or been declared effective or any amendment or supplement
to the Prospectus, any Issuer Free Writing Prospectus shall have been filed or distributed, (ii)&nbsp;of the receipt of any comments from
the Commission, (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement
to the Prospectus, including any document incorporated by reference therein, or for additional information, including, but not limited
to, any request for information concerning any oral or written communication with potential investors and undertaken in reliance on Section&nbsp;5(d)&nbsp;of
the Securities Act., (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus, the Prospectus, or of
the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of
any proceedings for any of such purposes or of any examination pursuant to Section&nbsp;8(d)&nbsp;or 8(e)&nbsp;of the 1933 Act concerning
the Registration Statement, (v)&nbsp;of the occurrence of any event or development at any time when a prospectus relating to the Securities
is (or, but for the exception afforded by Rule&nbsp;172 of the 1933 Act Regulations (&ldquo;<B><I>Rule&nbsp;172</I></B>&rdquo;), would
be) required by the 1933 Act to be delivered in connection with sales of the Securities (the &ldquo;<B><I>Prospectus Delivery Period</I></B>&rdquo;)
as a result of which the Prospectus, the General Disclosure Package, any Issuer Free Writing Prospectus as then amended or supplemented
would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances existing when the Prospectus, the General Disclosure Package, any such Issuer Free Writing Prospectus
is delivered to a purchaser, not misleading; and (vi)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A of
the 1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule&nbsp;424(b), in
the manner and within the time period required by Rule&nbsp;424(b)&nbsp;(without reliance on Rule&nbsp;424(b)(8)), and will take such
steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule&nbsp;424(b)&nbsp;was
received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will use commercially
reasonable efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or
suspending the use of any preliminary prospectus, the Prospectus or suspending any such qualification of the Securities and, if any such
order is issued, will use commercially reasonable efforts to obtain as soon as possible the withdrawal thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Continued
Compliance with Securities Laws</I></B>. The Company will comply with the 1933 Act and the 1933 Act Regulations during the Prospectus
Delivery Period so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the Registration
Statement, the General Disclosure Package and the Prospectus. If at any time during the Prospectus Delivery Period any event shall occur
or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend
the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii)&nbsp;amend or supplement
the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be, will
not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein
not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration
Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements
of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)&nbsp;give the Representatives notice of such event, (B)&nbsp;prepare
any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the General
Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use,
furnish the Representatives with copies of any such amendment or supplement and (C)&nbsp;file with the Commission any such amendment or
supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representatives or counsel for
the Underwriters shall reasonably object unless the Company reasonably believes that the failure to file or use such amendment or supplement
would constitute a violation of law or subject it to liability. The Company will furnish to the Underwriters such number of copies of
such amendment or supplement as the Underwriters may reasonably request. The Company has given the Representatives notice of any filings
made pursuant to the 1934 Act or 1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the Representatives
notice of its intention to make any such filing from the Applicable Time to the Closing Time and will furnish the Representatives with
copies of any such documents a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any
such document to which the Representatives or counsel for the Underwriters shall reasonably object unless the Company reasonably believes
that the failure to file or use such amendment or supplement would constitute a violation of law or subject it to liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Delivery
of Registration Statements</I></B>. The Company has furnished or will deliver to the Representatives and to counsel for the Underwriters,
without charge, signed copies of the Registration Statement as originally filed and each amendment thereto (including exhibits filed therewith)
and signed copies of all consents and certificates of experts, and will also deliver to the Representatives, without charge, a conformed
copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) for each of the Underwriters. The
copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Delivery
of Prospectuses</I></B>. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus
as the Representatives may reasonably request on behalf of the Underwriters, and the Company hereby consents to the use of such copies
for purposes permitted by the 1933 Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus
relating to the Securities is (or, but for the exception afforded by Rule&nbsp;172, would be) required to be delivered under the 1933
Act, such number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and
any amendments or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof
filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Blue
Sky Qualifications</I></B>. The Company will use its commercially reasonable efforts, in cooperation with the Underwriters, to qualify
the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign)
as the Representatives may designate and to maintain such qualifications in effect so long as required to complete the distribution of
the Securities; provided, however, that the Company shall not be obligated to file any general consent to service of process or to qualify
as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation
in respect of doing business in any jurisdiction in which it is not otherwise so subject.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Rule&nbsp;158</I></B>.
The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its securityholders
as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the
last paragraph of Section&nbsp;11(a)&nbsp;of the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Use
of Proceeds</I></B>. The Company will use the net proceeds received by it from the sale of the Securities in the manner specified in the
Registration Statement, the General Disclosure Package and the Prospectus under &ldquo;Use of Proceeds.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Listing</I></B>.
The Company will use its commercially reasonable efforts to cause the Securities to be listed on the Nasdaq Stock Market LLC, subject
to notice of issuance, and to maintain the listing of the Common Stock (including the Securities) on the Nasdaq Stock Market LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Restriction
on Sale of Securities</I></B>. During a period of 90 days from the date of the Prospectus (the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo;),
the Company will not, without the prior written consent of Cantor, (i)&nbsp;issue more than 100,000 shares of Common Stock or options
to purchase shares of Common Stock to consultants pursuant to the Company&rsquo;s equity incentive plans, (ii)&nbsp;directly or indirectly,
offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable
or exchangeable for shares of Common Stock or file any registration statement under the 1933 Act with respect to any of the foregoing
or (iii)&nbsp;enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly,
the economic consequence of ownership of shares of Common Stock, whether any such swap or transaction described in <U>clause (ii)</U>&nbsp;or
<U>(iii)</U>&nbsp;above is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise. The foregoing
sentence shall not apply to (A)&nbsp;the Securities to be sold hereunder, (B)&nbsp;any shares of Common Stock issued by the Company upon
the exercise of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the Registration
Statement, the General Disclosure Package and the Prospectus, (C)&nbsp;shares of Common Stock issued by the Company as a result of anti-dilution
provisions in the Company&rsquo;s amended and restated certificate of incorporation as then in effect, (D)&nbsp;any shares of Common Stock
issued or options to purchase Common Stock granted pursuant to employee benefit plans of the Company referred to in the Registration Statement,
the General Disclosure Package and the Prospectus and (E)&nbsp;the grant or issuance of equity awards not exercisable during the Lock-Up
Period pursuant to the Company&rsquo;s equity incentive plans; provided that, in each case, the recipient of such shares of Common Stock
or other securities is subject to substantially the same restrictions as those contained in this <U>Section&nbsp;3(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Reporting
Requirements</I></B>. The Company, during the period when a Prospectus relating to the Securities is (or, but for the exception afforded
by Rule&nbsp;172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission
pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations. Additionally, the Company shall report
the use of proceeds from the issuance of the Securities to the extent required under Rule&nbsp;463 under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Issuer
Free Writing Prospectuses</I></B>. The Company agrees that, unless it obtains the prior written consent of the Representatives, it will
not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by
the Company under Rule&nbsp;433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses
listed on <U>Schedule B-2</U> hereto and any &ldquo;road show that is a written communication&rdquo; within the meaning of Rule&nbsp;433(d)(8)(i)&nbsp;that
has been reviewed by the Representatives. The Company represents that it has treated or agrees that it will treat each such free writing
prospectus consented to, or deemed consented to, by the Representatives as an &ldquo;issuer free writing prospectus,&rdquo; as defined
in Rule&nbsp;433. The Company represents that it has complied and will comply with the applicable requirements of Rule&nbsp;433 with respect
thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of
an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus
conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus
or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly
notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate
or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section&nbsp;4. Payment of Expenses.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Expenses</I></B>.
The Company will pay or cause to be paid all expenses incident to the performance of its obligations under this Agreement, including (i)&nbsp;the
preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each
amendment thereto, (ii)&nbsp;the preparation, printing and delivery to the Underwriters of copies of each preliminary prospectus, each
Issuer Free Writing Prospectus and the Prospectus and any amendments or supplements thereto and any costs associated with electronic delivery
of any of the foregoing by the Underwriters to investors, (iii)&nbsp;the preparation, issuance and delivery of the Securities pursuant
to this Agreement, including any stock or other transfer taxes and any stamp or other duties payable upon the sale, issuance or delivery
of the Securities to the Underwriters or the sale of the Securities by the Underwriters, (iv)&nbsp;the fees and disbursements of the Company&rsquo;s
counsel, accountants and other advisors, (v)&nbsp;the qualification of the Securities under securities laws in accordance with the provisions
of <U>Section&nbsp;3(e)</U>&nbsp;hereof, including filing fees and the fees and disbursements of counsel for the Underwriters in connection
therewith and in connection with the preparation of a blue sky survey and any supplement thereto, <I>provided however</I> that such fees
and disbursements of counsel for the Underwriters shall not exceed $5,000, (vi)&nbsp;the fees and expenses of any transfer agent or registrar
for the Securities, (vii)&nbsp;the reasonable out-of-pocket costs and expenses of the Company relating to investor presentations or any
 &ldquo;road show&rdquo; undertaken in connection with the marketing of the Securities, including without limitation, expenses associated
with the production of road show slides and graphics, fees and expenses of any consultants engaged by the Company in connection with the
road show presentations, travel and lodging expenses of the representatives and employees of the Company and any such consultants, (viii)&nbsp;the
filing fees incident to, and the reasonable fees and disbursements of counsel to the Underwriters in connection with, the review by, and
clearance of the offering with, FINRA of the terms of the sale of the Securities, <I>provided however</I> that such fees and disbursements
of counsel for the Underwriters shall not exceed $10,000, (ix)&nbsp;the fees and expenses incurred in connection with the listing of the
Securities on the Nasdaq Stock Market LLC, (x)&nbsp;the costs and expenses (including, without limitation, any damages or other amounts
payable in connection with legal or contractual liability) associated with the reforming of any contracts for sale of the Securities made
by the Underwriters caused by a breach of the representation contained in the third sentence of <U>Section&nbsp;1(a)(ii)</U>&nbsp;and
<U>(xi)</U>&nbsp;all other reasonable out-of-pocket expenses incurred by the Underwriters in connection with the offering of the Securities,
including travel, document production and distribution and database and research expenses and the reasonable fees and disbursements of
the Underwriters&rsquo; outside legal counsel documented in writing, provided however that all such reimbursable expenses, fees and disbursements
under this Section&nbsp;4(a)&nbsp;shall not exceed $75,000 in the aggregate without the prior written consent of the Company, which shall
not be unreasonably withheld. It is understood and agreed that except as otherwise provided in this <U>Section&nbsp;4(a)</U>, the Underwriters
shall pay all of their costs and expenses, including fees and disbursements of their counsel, stock transfer taxes payable on their resale
of any of the Securities, travel and lodging costs and expenses of the Representatives related to the road show and any advertising expenses
connected with any offers made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Termination
of Agreement</I></B>. If this Agreement is terminated by the Representatives in accordance with the provisions of <U>Section&nbsp;5</U>,
<U>Section&nbsp;9(a)(i)</U>, <U>9(a)(iii)</U>&nbsp;or <U>Section&nbsp;11</U> hereof, the Company shall reimburse the Underwriters for
their out-of-pocket expenses, including the fees and disbursements of counsel for the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;5.
Conditions of Underwriters&rsquo; Obligations.</B></FONT> The obligations of the Underwriters hereunder are subject to the accuracy of
the representations and warranties of the Company contained herein or in certificates of any officer of the Company delivered pursuant
to the provisions hereof, to the performance by the Company of the covenants and other obligations hereunder, and to the following further
conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Effectiveness
of Registration Statement; Rule&nbsp;430B Information</I></B>. The Registration Statement, including any Rule&nbsp;462(b)&nbsp;Registration
Statement, has been declared effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary
prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the
Company&rsquo;s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information
to the reasonable satisfaction of counsel to the Company and counsel to the Underwriters. A prospectus containing the Rule&nbsp;430B Information
shall have been filed with the Commission in the manner and within the time frame required by Rule&nbsp;424(b)&nbsp;without reliance on
Rule&nbsp;424(b)(8)&nbsp;or a post-effective amendment providing such information shall have been filed with, and declared effective by,
the Commission in accordance with the requirements of Rule&nbsp;430B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Opinion
of Counsel for Company</I></B>. At the Closing Time, the Representatives shall have received the favorable opinion and negative assurance
letter, dated as of the Closing Time and relating to the Securities, of Dorsey&nbsp;&amp; Whitney LLP, counsel for the Company, in the
form and substance reasonably satisfactory to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Opinion
of Counsel for Underwriters</I></B>. At the Closing Time, the Representatives shall have received the favorable opinion and negative assurance
letter, dated the Closing Time, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters, together with signed
or reproduced copies of such letter for each of the other Underwriters, in form and substance reasonably satisfactory to the Representatives,
and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Officers&rsquo;
Certificate</I></B>. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which information
is given in the Registration Statement, the General Disclosure Package or the Prospectus, any Material Adverse Effect, and the Representatives
shall have received a certificate of the Chief Executive Officer or the President of the Company and of the chief financial or chief accounting
officer of the Company, dated the Closing Time, to the effect that (i)&nbsp;there has been no such Material Adverse Effect, (ii)&nbsp;the
representations and warranties of the Company in this Agreement are true and correct with the same force and effect as though expressly
made at and as of the Closing Time, (iii)&nbsp;the Company has complied with all agreements and satisfied all conditions on its part to
be performed or satisfied at or prior to the Closing Time, and (iv)&nbsp;no stop order suspending the effectiveness of the Registration
Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus or the Prospectus
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge, contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Accountant&rsquo;s
Comfort Letter</I></B>. At the time of the execution of this Agreement, the Representatives shall have received from Plante&nbsp;&amp;
Moran, PLLC a letter, dated such date, in form and substance satisfactory to the Representatives, together with signed or reproduced copies
of such letter for each of the other Underwriters containing statements and information of the type ordinarily included in accountants&rsquo;
 &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements and certain financial information contained in
the Registration Statement, the General Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Bring-down
Comfort Letter</I></B>. At the Closing Time, the Representatives shall have received from Plante&nbsp;&amp; Moran, PLLC a letter, dated
as of the Closing Time, to the effect that they reaffirm the statements made in the letter furnished pursuant to <U>subsection (e)</U>&nbsp;of
this <U>Section&nbsp;5</U>, except that the specified date referred to shall be a date not more than three business days prior to the
Closing Time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>No
Objection</I></B>. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting
terms and arrangements relating to the offering of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Lock-up
Agreements</I></B>. At the date of this Agreement, the Representatives shall have received an agreement substantially in the form of <U>Exhibit&nbsp;A</U>
hereto signed by the persons listed on <U>Schedule D</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Additional
Documents</I></B>. At the Closing Time and at each Date of Delivery (if any), the Representatives and counsel for the Underwriters shall
have been furnished with such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the
issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties,
or the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance
and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Representatives and counsel
for the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Termination
of Agreement</I></B>. If any condition specified in this <U>Section&nbsp;5</U> shall not have been fulfilled when and as required to be
fulfilled, then this Agreement may be terminated by the Representatives by notice to the Company at any time at or prior to the Closing
Time, and such termination shall be without liability of any party to any other party except as provided in <U>Section&nbsp;4</U> hereof
and except that <U>Sections 1</U>, <U>6</U>, <U>7</U>, <U>8</U>, <U>15</U> and <U>16</U> shall survive any such termination and remain
in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Delivery
of Prospectuses</I></B>. The Company shall have complied with the provisions of <U>Section&nbsp;3(d)</U>&nbsp;hereof with respect to the
furnishing of prospectuses on the business day next succeeding the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Approval
of Listing</I></B>. At the Closing Time, the Securities shall have been approved for listing on the Nasdaq Capital Market, subject only
to official notice of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Opinion
of Intellectual Property Counsels for Company</I></B>. At the Closing Time, the Representatives shall have received the favorable opinion,
dated as of the Closing Time and relating to the Company&rsquo;s intellectual property, of each of Sheridan Ross PC and Arent Fox LLP,
intellectual property counsels for the Company, in form and substance reasonably satisfactory to the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Chief
Financial Officer&rsquo;s Certificate</I></B>. At the time of the execution of this Agreement and at the Closing Time, the Representatives
shall have received a certificate executed by the Chief Financial Officer of the Company, in the form and substance reasonably satisfactory
to the Representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section&nbsp;6. Indemnification.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Indemnification
of Underwriters</I></B>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as such term is defined in
Rule&nbsp;501(b)&nbsp;under the 1933 Act (each, an &ldquo;<B><I>Affiliate</I></B>&rdquo;)), its selling agents and each person, if any,
who controls any Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement (or any amendment thereto), including the Rule&nbsp;430B Information,
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein
not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A)&nbsp;in any preliminary
prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto)
or (B)&nbsp;in any materials or information provided to investors by, or with the prior written approval of, the Company in connection
with the marketing of the offering of the Securities (&ldquo;<B><I>Marketing Materials</I></B>&rdquo;), including any roadshow or investor
presentations made to investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary
prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus or in any Marketing Materials of a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement
of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever
based upon any such untrue statement or omission, or any such alleged untrue statement or omission; <I>provided</I> that (subject to <U>Section&nbsp;6(d)</U>&nbsp;below)
any such settlement is effected with the written consent of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">against
any and all expense whatsoever, as incurred (including the fees and disbursements of one counsel (in addition to any relevant local counsel)
chosen by the Representatives), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation
or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement
or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under <U>(i)</U>&nbsp;or
<U>(ii)</U>&nbsp;above;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>provided</I></FONT>,
<I>however</I>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out
of any untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto),
including the Rule&nbsp;430B Information, any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package
or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Indemnification
of Company, Directors and Officers</I></B>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company,
its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the
meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act against any and all loss, liability, claim, damage and expense
described in the indemnity contained in <U>subsection (a)</U>&nbsp;of this Section, as incurred, but only with respect to untrue statements
or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including the
Rule&nbsp;430B Information, any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus
(or any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Actions
against Parties; Notification</I></B>. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying
party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying
party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result
thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement.
In the case of parties indemnified pursuant to <U>Section&nbsp;6(a)</U>&nbsp;above, counsel to the indemnified parties shall be selected
by the Representatives, and, in the case of parties indemnified pursuant to <U>Section&nbsp;6(b)</U>&nbsp;above, counsel to the indemnified
parties shall be selected by the Company. An indemnifying party may participate at its own expense in the defense of any such action;
<I>provided</I>, <I>however</I>, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also
be counsel to the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel
(in addition to any relevant local counsel) separate from their own counsel for all indemnified parties in connection with any one action
or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying
party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment
with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any
claim whatsoever in respect of which indemnification or contribution could be sought under this <U>Section&nbsp;6</U> or <U>Section&nbsp;7</U>
hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent
(i)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation,
proceeding or claim and (ii)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act by or on
behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Settlement
without Consent if Failure to Reimburse</I></B>. If at any time an indemnified party shall have requested an indemnifying party to reimburse
the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the
nature contemplated by <U>Section&nbsp;6(a)(ii)</U>&nbsp;hereof effected without its written consent if (i)&nbsp;such settlement is entered
into more than 60 days after receipt by such indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have
received notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii)&nbsp;such indemnifying
party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;7.
Contribution.</B></FONT> If the indemnification provided for in <U>Section&nbsp;6</U> hereof is for any reason unavailable to or insufficient
to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such
indemnified party, as incurred, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company,
on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii)&nbsp;if
the allocation provided by <U>clause (i)</U>&nbsp;above is not permitted by applicable law, in such proportion as is appropriate to reflect
not only the relative benefits referred to in <U>clause (i)</U>&nbsp;above but also the relative fault of the Company, on the one hand,
and of the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, liabilities,
claims, damages or expenses, as well as any other relevant equitable considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relative benefits received by the Company,
on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement
shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this
Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by the Underwriters,
on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate public offering price of the Securities
as set forth on the cover of the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relative fault of the Company, on the one hand,
and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue
statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or
by the Underwriters and the parties&rsquo; relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company and the Underwriters agree that it
would not be just and equitable if contribution pursuant to this <U>Section&nbsp;7</U> were determined by <I>pro rata</I> allocation (even
if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above in this <U>Section&nbsp;7</U>. The aggregate amount of losses, liabilities, claims, damages
and expenses incurred by an indemnified party and referred to above in this <U>Section&nbsp;7</U> shall be deemed to include any legal
or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue
or alleged untrue statement or omission or alleged omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the provisions of this <U>Section&nbsp;7</U>,
no Underwriter shall be required to contribute any amount in excess of the underwriting commissions received by such Underwriter in connection
with the Securities underwritten by it and distributed to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f)&nbsp;of the 1933 Act) shall be entitled to contribution from any person who was not guilty of
such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of this <U>Section&nbsp;7</U>, each
person, if any, who controls an Underwriter within the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act and
each Underwriter&rsquo;s Affiliates and selling agents shall have the same rights to contribution as such Underwriter, and each director
of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within
the meaning of Section&nbsp;15 of the 1933 Act or Section&nbsp;20 of the 1934 Act shall have the same rights to contribution as the Company.
The Underwriters&rsquo; respective obligations to contribute pursuant to this <U>Section&nbsp;7</U> are in proportion to the number of
Securities set forth opposite their respective names in <U>Schedule A</U> hereto and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;8.
Representations, Warranties and Agreements to Survive.</B></FONT> All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i)&nbsp;any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any
Underwriter, its officers and directors, or any person controlling the Company and (ii)&nbsp;delivery of and payment for the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Section&nbsp;9. Termination of Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Termination</I></B>.
The Representatives may terminate this Agreement, by notice to the Company, at any time at or prior to the Closing Time (i)&nbsp;if there
has been, in the judgment of the Representatives, since the time of execution of this Agreement or since the respective dates as of which
information is given in the Registration Statement, the General Disclosure Package or the Prospectus, a Material Adverse Effect, or (ii)&nbsp;if
there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any
outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change
in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the
judgment of the Representatives, impracticable or inadvisable to proceed with the completion of the offering or to enforce contracts for
the sale of the Securities, or (iii)&nbsp;if trading in any securities of the Company has been suspended or materially limited by the
Commission or the Nasdaq Stock Market LLC, or (iv)&nbsp;if trading generally on the New York Stock Exchange or on the Nasdaq Stock Market
LLC has been suspended or materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have
been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or (v)&nbsp;a material
disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream
or Euroclear systems in Europe, or (vi)&nbsp;if a banking moratorium has been declared by either federal or New York authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><I>Liabilities</I></B>.
If this Agreement is terminated pursuant to this <U>Section&nbsp;9</U>, such termination shall be without liability of any party to any
other party except as provided in <U>Section&nbsp;4</U> hereof, and provided further that <U>Sections 1</U>, <U>6</U>, <U>7</U>, <U>8</U>,
<U>9(b)</U>, <U>11</U>, <U>15</U> and <U>16</U> shall survive such termination and remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;10.
Default by One or More of the Underwriters.</B></FONT> If one or more of the Underwriters shall fail at the Closing Time or a Date of
Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the &ldquo;<B><I>Defaulted Securities</I></B>&rdquo;),
the Representatives shall have the right, within 24 hours thereafter, make arrangements for one or more of the non-defaulting Underwriters,
or any other underwriters reasonably satisfactory to the Company, to purchase all, but not less than all, of the Defaulted Securities
in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such
arrangements within such 24-hour period, then: if the number of Defaulted Securities does not exceed 10% of the number of Securities to
be purchased on such date, each of the non-defaulting Underwriters shall be obligated, severally and not jointly, to purchase the full
amount thereof in the proportions that their respective underwriting obligations hereunder bear to the underwriting obligations of all
non-defaulting Underwriters,. Any termination of this Agreement pursuant to this <U>Section&nbsp;10</U> shall be without liability on
the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in <U>Section&nbsp;4</U>
hereof and provided further that <U>Sections 1</U>, <U>6</U>, <U>7</U>, <U>8</U>, <U>9(b)</U>, <U>11</U>, <U>15</U> and <U>16</U> shall
survive such termination and remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">No action taken pursuant to this <U>Section&nbsp;10</U>
shall relieve any defaulting Underwriter from liability in respect of its default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event of any such default which does not
result in a termination of this Agreement, either (i)&nbsp;the Representatives or (ii)&nbsp;the Company shall have the right to postpone
the Closing Time for a period not exceeding seven days in order to effect any required changes in the Registration Statement, the General
Disclosure Package or the Prospectus or in any other documents or arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;11.
Default by the Company.</B></FONT> If the Company shall fail at the Closing Time or a Date of Delivery, as the case may be, to sell the
number of Securities that it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of
any nondefaulting party; provided, however, that the provisions of <U>Sections 1</U>, <U>4</U>, <U>6</U>, <U>7</U>, <U>8</U>, <U>9(b)</U>,
<U>11</U>, <U>15</U> and <U>16</U> shall remain in full force and effect. No action taken pursuant to this Section&nbsp;shall relieve
the Company from liability, if any, in respect of such default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;12.
Notices.</B></FONT> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if
mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to (i)&nbsp;c/o Cantor
Fitzgerald&nbsp;&amp; Co., 499 Park Avenue, New York, New York 10022, Attention: General Counsel and (ii)&nbsp;c/o Canaccord Genuity LLC,
535 Madison Avenue, 2<SUP>nd</SUP> Floor, New York, New York, 10022, Attention: Syndicate Department, Attention: General Counsel; and
notices to the Company shall be directed to it at Aytu BioPharma,&nbsp;Inc., 373 Inverness Parkway, Suite&nbsp;206 Englewood, CO 80112,
Attention: Chief Financial Officer (facsimile: (720) 437-6580).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the requirements of the USA
Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and
record information that identifies their respective clients, including the Company, which information may include the name and address
of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;13.
No Advisory or Fiduciary Relationship.</B></FONT> The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Securities
pursuant to this Agreement, including the determination of the public offering price of the Securities and any related discounts and commissions,
is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the Underwriters, on the other hand, (b)&nbsp;in
connection with the offering of the Securities and the process leading thereto, each Underwriter is and has been acting solely as a principal
and is not the agent or fiduciary of the Company or its respective stockholders, creditors, employees or any other party, (c)&nbsp;no
Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering of
the Securities or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company
on other matters) and no Underwriter has any obligation to the Company with respect to the offering of the Securities except the obligations
expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of transactions
that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory
or tax advice with respect to the offering of the Securities and the Company has consulted its own respective legal, accounting, regulatory
and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;14.
Parties.</B></FONT> This Agreement shall each inure to the benefit of and be binding upon the Underwriters, the Company and their respective
successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation,
other than the Underwriters, the Company and their respective successors and the controlling persons and officers and directors referred
to in <U>Sections 6</U> and <U>7</U> and their heirs and legal representatives, any legal or equitable right, remedy or claim under or
in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to
be for the sole and exclusive benefit of the Underwriters, the Company and their respective successors, and said controlling persons and
officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser
of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase. In all dealings hereunder, the
Representatives, acting jointly, shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled to act and
rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by the Representatives, acting jointly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;15.
Trial by Jury.</B></FONT> The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and
affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right
to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;16.
GOVERNING LAW.</B></FONT> THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED
BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;17.
TIME.</B></FONT> TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO
NEW YORK CITY TIME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;18.
Partial Unenforceability.</B></FONT> The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall
not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or provision
of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;19.
Counterparts.</B></FONT> This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original,
but all such counterparts shall together constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;20.
Effect of Headings.</B></FONT> The Section&nbsp;headings herein are for convenience only and shall not affect the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Section&nbsp;21.
Entire Agreement.</B></FONT> This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company
and the Underwriters with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<B><I>Remainder of the page&nbsp;intentionally
left blank; signature page&nbsp;follows</I></B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your understanding
of our agreement, please sign and return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement among the Underwriters and the Company in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: left">Very truly yours,</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">AYTU BIOPHARMA,&nbsp;INC.</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 4%">&nbsp;</TD><TD STYLE="text-align: justify; width: 46%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:</TD><TD STYLE="border-bottom: Black thin solid; text-align: justify">/s/ Josh Disbrow</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Name: Josh Disbrow</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Title: Chief Executive Officer</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">CONFIRMED AND ACCEPTED,</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">as of the date first above written:</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">CANTOR FITZGERALD&nbsp;&amp; CO.</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%">&nbsp;</TD><TD STYLE="text-align: left; width: 46%">&nbsp;</TD><TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD><TD STYLE="border-bottom: Black thin solid; text-align: left">/s/ Sage Kelly</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">Authorized Signatory</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD COLSPAN="2">CANACCORD GENUITY LLC</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>By:</TD><TD STYLE="border-bottom: Black thin solid; text-align: left">/s/ Jennifer Pardi</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">Authorized Signatory</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For themselves and as Representatives of the other Underwriters named
in <U>Schedule A</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Schedule A</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Name</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold"><B>Number of<FONT STYLE="font-size: 10pt"><BR> Shares to&nbsp;be<BR> Purchased</FONT></B></TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of<BR> Pre-Funded Warrants&nbsp;to<BR> be<BR> Purchased</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: bold 10pt Times New Roman, Times, Serif">Number of<BR> Warrants&nbsp;to<BR> be<BR> Purchased</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">Cantor Fitzgerald&nbsp;&amp; Co.</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">13,978,780</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,137,500</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">15,116,280</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Canaccord Genuity LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,527,034</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">612,500</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,139,534</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.25in">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21,505,814</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,750,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">23,255,814</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B><I>Schedule B-1</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRICING TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer: Aytu BioPharma,&nbsp;Inc. (Nasdaq: AYTU) (the &ldquo;<B><I>Company</I></B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities to be Sold:</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,505,814</FONT> <FONT STYLE="font-size: 10pt">shares of Common Stock</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-Funded Warrants to purchase </FONT>1,750,000 shares of Common Stock</TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase </FONT><FONT STYLE="font-size: 10pt">23,255,814 shares of Common Stock</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering Price:</FONT></TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT><FONT STYLE="font-size: 10pt">0.43 per share of Common Stock and Warrant to purchase one share of Common Stock</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT><FONT STYLE="font-size: 10pt">0.429 per&nbsp;Pre-Funded&nbsp;Warrant and Warrant to purchase one share of Common Stock</FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">($</FONT><FONT STYLE="font-size: 10pt">0.001 of which will be payable upon exercise of the&nbsp;Pre-Funded&nbsp;Warrant)</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrant
Exercise Price:</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify">$0.43 per Warrant
Share</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriting
Discounts and Commissions:</FONT></TD>
<TD STYLE="vertical-align: top; text-align: justify">6.5%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B><I>Schedule B-2</I></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FREE WRITING PROSPECTUSES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B><I>Schedule C</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIST OF PERSONS AND ENTITIES SUBJECT TO LOCK-UP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshua R. Disbrow</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark Oki</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael E. Macaluso</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carl C. Dockery</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John A. Donofiro,&nbsp;Jr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vivian Liu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gary V. Cantrell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LOCK-UP AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form&nbsp;of
pre-funded warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Annex
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form&nbsp;of
Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>tm2222304d3_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AYTU
BIOPHARMA,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 45%; text-align: left"><FONT STYLE="font-size: 10pt">Warrant Shares:</FONT></TD><TD STYLE="text-align: justify; width: 55%"><FONT STYLE="font-size: 10pt">Initial
                                            Exercise Date: [&bull;], 2022</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Aytu BioPharma,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one
share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;1</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the
 &ldquo;<U>Underwriting Agreement</U>&rdquo;), dated August&nbsp;9, 2022, among the Company and the underwriters signatory thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;2</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement
Period (as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of
Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded
to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise
price of $0.01 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The
Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance
or for any reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining
unpaid exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in
which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(A)&nbsp;= as
applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo;
(as defined in Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at
the option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular
trading hours&rdquo; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after
the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on
the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is
both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such
Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B)&nbsp;= the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(X)&nbsp;= the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company agrees not
to take any position contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&nbsp;(New York
City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such
system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of
a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one
(1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty,
for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date)
for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s)&nbsp;of Exercise delivered on or prior to 12:00
p.m.&nbsp;(New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Underwriting
Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)&nbsp;by 4:00 p.m.&nbsp;(New York City time) on
the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that
payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">iv.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to
purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
 &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount
obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with
the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at
the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">v.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vi.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">vii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify"><U>Holder&rsquo;s Exercise Limitations</U>.
                                            The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
                                            right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to
                                            the extent that after giving effect to such issuance after exercise as set forth on the applicable
                                            Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
                                            Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
                                            (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess
                                            of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing
                                            sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
                                            and Attribution Parties shall include the number of shares of Common Stock issuable upon
                                            exercise of this Warrant with respect to which such determination is being made, but shall
                                            exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise
                                            of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or
                                            any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the
                                            unexercised or nonconverted portion of any other securities of the Company (including, without
                                            limitation, any other Common Stock Equivalents) subject to a limitation on conversion or
                                            exercise analogous to the limitation contained herein beneficially owned by the Holder or
                                            any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding
                                            sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated
                                            in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations
                                            promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
                                            to the Holder that such calculation is in compliance with Section&nbsp;13(d)&nbsp;of the
                                            Exchange Act and the Holder is solely responsible for any schedules required to be filed
                                            in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies,
                                            the determination of whether this Warrant is exercisable (in relation to other securities
                                            owned by the Holder together with any Affiliates and Attribution Parties) and of which portion
                                            of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
                                            of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether
                                            this Warrant is exercisable (in relation to other securities owned by the Holder together
                                            with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
                                            in each case subject to the Beneficial Ownership Limitation, and the Company shall have no
                                            obligation to verify or confirm the accuracy of such determination. In addition, a determination
                                            as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
                                            the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes
                                            of this Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock,
                                            a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
                                            Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case
                                            may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a more recent
                                            written notice by the Company or the Transfer Agent setting forth the number of shares of
                                            Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company
                                            shall within one Trading Day confirm orally and in writing to the Holder the number of shares
                                            of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of
                                            Common Stock shall be determined after giving effect to the conversion or exercise of securities
                                            of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
                                            since the date as of which such number of outstanding shares of Common Stock was reported.
                                            The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of the number of
                                            shares of the Common Stock outstanding immediately after giving effect to the issuance of
                                            shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to
                                            the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
                                            Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds
                                            9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
                                            to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
                                            and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in
                                            the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after
                                            such notice is delivered to the Company. The provisions of this paragraph shall be construed
                                            and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to
                                            correct this paragraph (or any portion hereof) which may be defective or inconsistent with
                                            the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
                                            necessary or desirable to properly give effect to such limitation. The limitations contained
                                            in this paragraph shall apply to a successor holder of this Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;3</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to
the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership
of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held
in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder
has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock
or 50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such
Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner
reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall
cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with
the provisions of this Section&nbsp;3(d)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto
and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and
the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its
last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record
or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date
on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and
the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Voluntary
Adjustment By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market, the Company may at any time during the term
of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;4</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form
to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><U>Section&nbsp;5</U>.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company
further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of
issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law
or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Underwriting Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">AYTU
    BIOPHARMA,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Joshua Disbrow</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer &nbsp;</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt; text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">AYTU
BIOPHARMA,&nbsp;INC.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(1)</FONT>&#8239;<FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(2)</FONT>&#8239;<FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[ ] [if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection
2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">(3)</FONT>&#8239;<FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Name of Investing Entity:
                            _____________________________________________________________________________________________________</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>:_______________________________________________________________________________</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Name of Authorized Signatory: _________________________________________________________________________________________________</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Title of Authorized Signatory:&#8239; _________________________________________________________________________________________________</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify">Date:&#8239; ____________________________________________________________________________________________________________________</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 405.75pt"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please
        Print)</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Phone Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Email Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _____________ ___, ______</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _____________________________</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">: ______________________________</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>tm2222304d3_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>aytu
biopharma, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
Shares: _______</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Initial
Exercise Date: [&#9679;], 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">THIS
COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the
 &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m.&nbsp;(New
York City time) on</FONT> [&#9679;], 202[&#9679;] (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and
purchase from Aytu BioPharma,&nbsp;Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to
adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;1</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section&nbsp;1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.&nbsp;(New
York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock
is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Convertible
Securities</U>&rdquo; means any stock or other security (other than Options) that is at any time and under any circumstances, directly
or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares
of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded
Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose, consultants of the Company pursuant to any existing stock or option
plan duly adopted for such purpose, or officers of the Company pursuant to an inducement stock or option grant pursuant to Nasdaq Listing
Rule&nbsp;5635(c)(4), in each case as approved by a majority of the non-employee members of the Board of Directors or a majority of the
members of a committee of non-employee directors established for such purpose for services rendered to the Company; (b)&nbsp;securities
upon the exercise or exchange of or conversion of any securities issued hereunder and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Warrant, provided that such securities have
not been amended since the date of this Warrant to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such
securities, (c)&nbsp;subsequent to the first anniversary of the date of this Warrant, securities issuable upon the occurrence of any outstanding
milestone obligations pursuant to agreements entered into by the Company prior to the date of this Warrant or (d)&nbsp;securities issued
pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that
such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the 90 days following the date of this Warrant,
and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Event
Market Price</U>&rdquo; means, with respect to any Stock Combination Event Date, </FONT>the quotient determined by dividing (x)&nbsp;the
sum of the VWAP of the Common Stock for each of the five (5)&nbsp;lowest Trading Days during the twenty (20) consecutive Trading Day period
ending and including the Trading Day immediately preceding the sixteenth (16th) Trading Day after such Stock Combination Event Date, divided
by (y)&nbsp;five (5). All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination,
recapitalization or other similar transaction during such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Options</U>&rdquo;
means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form&nbsp;S-3 (File No.&nbsp;333-248279).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Transfer
Agent</U>&rdquo; means Issuer Direct Corporation, the current transfer agent of the Company, with a mailing address of </FONT>One Glenwood
Ave, Suite&nbsp;1001, Raleigh, NC 27603 and an email address of<FONT STYLE="color: #1f497d"><B>&nbsp;</B></FONT>info@issuerdirect.com,
and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if
the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company in the offering in which this Warrant was issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;2</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company) of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period
(as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States
bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of Exercise.
No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of
any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of
a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $0.43, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="white-space: nowrap; width: 4%; text-align: left">(A) =</TD><TD STYLE="text-align: justify">as applicable: (i)&nbsp;the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both
executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule&nbsp;600(b)&nbsp;of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of
the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z)&nbsp;the
Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if
the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof
after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="white-space: nowrap; width: 4%; text-align: left">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="white-space: nowrap; width: 4%; text-align: left">(X) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a
cash exercise rather than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any
position contrary to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">i.</TD><TD STYLE="text-align: justify"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if
the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance
of the Warrant Shares to or resale of the Warrant Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise,
and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its
designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
in the Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of
the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the
number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise, and, in
the case of each of (i)&nbsp;and (iii), subject to the Company&rsquo;s receipt of the aggregate Exercise Price (such date, the &ldquo;<U>Warrant
Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period
following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject
to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable
Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery
Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.
The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a
number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery
of the Notice of Exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise, and the Company shall return all consideration
paid by the Holder for such shares upon such rescission. Notwithstanding anything herein to the contrary, the Company shall not be required
to make any cash payments to the Holder in lieu of issuance of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying
(1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the Company
each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in this paragraph,
and the Company shall have no obligation to verify or confirm the accuracy of such determination, provided that in making such representation,
the Holder is relying on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&rsquo;s most recent periodic
or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the Company or (C)&nbsp;a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of the Exchange
Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the
Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock
outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading Days confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of
Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant,
by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance
of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99%
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon
exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in
the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section&nbsp;2(e)&nbsp;to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;3</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
Upon Issuance of Common Stock</U>. If and whenever on or after the Initial Exercise Date, the Company grants, issues or sells, (or enters
into any agreement to grant, issue or sell), or in accordance with this Section&nbsp;3(b)&nbsp;is deemed to have issued or sold, any
shares of its Common Stock (including the issuance or sale of shares of Common Stock owned or held by or for the account of the Company,
but excluding any Excluded Issuances issued or sold or deemed to have been issued or sold) for a consideration per share (the &ldquo;<U>New
Issuance Price</U>&rdquo;) less than a price equal to the Exercise Price in effect immediately prior to such issuance or sale or deemed
issuance or sale (such Exercise Price then in effect is referred to herein as the &ldquo;<U>Applicable Price</U>&rdquo;) (the foregoing
a &ldquo;<U>Dilutive Issuance</U>&rdquo;), then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be
reduced to an amount equal to the New Issuance Price; provided, however, that (i)&nbsp;this Section&nbsp;3(b)&nbsp;shall be of no further
force or effect upon the second anniversary of a Stock Combination Event pursuant to Section&nbsp;3(d)&nbsp;and (ii)&nbsp;the Exercise
Price shall not be decreased pursuant to this Section&nbsp;3(b)&nbsp;to a price per Warrant Share lower than $0.116 subject to adjustment
for reverse and forward stock splits and the like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and the New Issuance Price under
this Section&nbsp;3(c)), the following shall be applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Issuance
of Options</U>. If the Company in any manner grants, issues or sells (or enters into any agreement to grant, issue or sell) any Options
and the lowest price per share for which one share of Common Stock is at any time issuable upon the exercise of any such Option or upon
conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the
terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued
and sold by the Company at the time of the granting, issuance or sale (or the time of execution of such agreement to grant, issue or sell,
as applicable) of such Option for such price per share. For purposes of this Section&nbsp;3(c)(i), the &ldquo;lowest price per share for
which one share of Common Stock is at any time issuable upon the exercise of any such Options or upon conversion, exercise or exchange
of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&rdquo; shall be equal
to (1)&nbsp;the lower of (x)&nbsp;the sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect
to any one share of Common Stock upon the granting, issuance or sale (or pursuant to the agreement to grant, issue or sell, as applicable)
of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise
of such Option or otherwise pursuant to the terms thereof and (y)&nbsp;the lowest exercise price set forth in such Option for which one
share of Common Stock is issuable (or may become issuable assuming all possible market conditions) upon the exercise of any such Options
or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant
to the terms thereof minus (2)&nbsp;the sum of all amounts paid or payable to the holder of such Option (or any other Person) upon the
granting, issuance or sale (or the agreement to grant, issue or sell, as applicable) such Option, upon exercise of such Option and upon
conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms
thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any
other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such
shares of Common Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms of or upon
the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Issuance
of Convertible Securities</U>. If the Company in any manner issues or sells (or enters into any agreement to issue or sell) any Convertible
Securities and the lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or
exchange thereof or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock shall be
deemed to be outstanding and to have been issued and sold by the Company at the time of the issuance or sale (or the time of execution
of such agreement to issue or sell, as applicable) of such Convertible Securities for such price per share. For the purposes of this Section&nbsp;3(c)(ii),
the &ldquo;lowest price per share for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange
thereof or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1)&nbsp;the lower of (x)&nbsp;the sum of the lowest amounts
of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale (or
pursuant to the agreement to issue or sell, as applicable) of the Convertible Security and upon conversion, exercise or exchange of such
Convertible Security or otherwise pursuant to the terms thereof and (y)&nbsp;the lowest conversion price set forth in such Convertible
Security for which one share of Common Stock is issuable (or may become issuable assuming all possible market conditions) upon conversion,
exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2)&nbsp;the sum of all amounts paid or payable to the holder
of such Convertible Security (or any other Person) upon the issuance or sale (or the agreement to issue or sell, as applicable) of such
Convertible Security plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such
Convertible Security (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon
the actual issuance of such Common Stock upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to
the terms thereof, and if any such issuance or sale of such Convertible Securities is made upon exercise of any Options for which adjustment
of this Warrant has been or is to be made pursuant to other provisions of this Section&nbsp;3(c), except as contemplated below, no further
adjustment of the Exercise Price shall be made by reason of such issuance or sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Change
in Option Price or Rate of Conversion</U>. If the purchase or exercise price provided for in any Options, the additional consideration,
if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any Convertible
Securities are convertible into or exercisable or exchangeable for Common Stock increases or decreases at any time (other than proportional
changes in conversion or exercise prices, as applicable, in connection with an event referred to in Section&nbsp;3(a)), the Exercise
Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would have been in effect at such
time had such Options or Convertible Securities provided for such increased or decreased purchase price, additional consideration or
increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold. For purposes of this Section&nbsp;3(c)(iii),
if the terms of any Option or Convertible Security that was outstanding as of the Initial Exercise Date are increased or decreased in
the manner described in the immediately preceding sentence, then such Option or Convertible Security and the Common Stock deemed issuable
upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment
pursuant to this Section&nbsp;3(c)&nbsp;shall be made if such adjustment would result in an increase of the Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Calculation
of Consideration Received</U>. If any Option and/or Convertible Security and/or Adjustment Right is issued in connection with the issuance
or sale or deemed issuance or sale of any other securities of the Company (as determined by the Holder, the &ldquo;<U>Primary Security</U>&rdquo;,
and such Option and/or Convertible Security and/or Adjustment Right, the &ldquo;<U>Secondary Securities</U>&rdquo; and together with the
Primary Security, each a &ldquo;<U>Unit</U>&rdquo;), together comprising one integrated transaction, the aggregate consideration per share
of Common Stock with respect to such Primary Security shall be deemed to be the lowest of (x)&nbsp;the purchase price of such Unit, (y)&nbsp;if
such Primary Security is an Option and/or Convertible Security, the lowest price per share for which one share of Common Stock is at any
time issuable upon the exercise or conversion of the Primary Security in accordance with Section&nbsp;3(c)(i)&nbsp;or 3(c)(ii)&nbsp;above
and (z)&nbsp;the lowest VWAP of the Common Stock on any Trading Day during the five (5)&nbsp;Trading Day period (the &ldquo;<U>Adjustment
Period</U>&rdquo;) immediately following the public announcement of such Dilutive Issuance (for the avoidance of doubt, if such public
announcement is released prior to the opening of the applicable Trading Market on a Trading Day, such Trading Day shall be the first Trading
Day in such five Trading Day period and if this Warrant is exercised, on any given Exercise Date during any such Adjustment Period, solely
with respect to such portion of this Warrant converted on such applicable Exercise Date, such applicable Adjustment Period shall be deemed
to have ended on, and included, the Trading Day immediately prior to such Exercise Date). If any Common Stock, Options or Convertible
Securities are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed to be
the net amount of consideration received by the Company therefor. If any Common Stock, Options or Convertible Securities are issued or
sold for a consideration other than cash, the amount of such consideration received by the Company will be the fair value of such consideration,
except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company
for such securities will be the arithmetic average of the VWAPs of such security for each of the five (5)&nbsp;Trading Days immediately
preceding the date of receipt. If any Common Stock, Options or Convertible Securities are issued to the owners of the non-surviving entity
in connection with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be
the fair value of such portion of the net assets and business of the non-surviving entity as is attributable to such Common Stock, Options
or Convertible Securities (as the case may be). The fair value of any consideration other than cash or publicly traded securities will
be determined jointly by the Company and the Holder. If such parties are unable to reach agreement within ten (10)&nbsp;days after the
occurrence of an event requiring valuation (the &ldquo;<U>Valuation Event</U>&rdquo;), the fair value of such consideration will be determined
within five (5)&nbsp;Trading Days after the tenth (10th) day following such Valuation Event by an independent, reputable appraiser jointly
selected by the Company and the Holder. The determination of such appraiser shall be final and binding upon all parties absent manifest
error and the fees and expenses of such appraiser shall be borne by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Record
Date</U>. If the Company takes a record of the holders of Common Stock for the purpose of entitling them (A)&nbsp;to receive a dividend
or other distribution payable in Common Stock, Options or in Convertible Securities or (B)&nbsp;to subscribe for or purchase Common Stock,
Options or Convertible Securities, then such record date will be deemed to be the date of the issuance or sale of the Common Stock deemed
to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting
of such right of subscription or purchase (as the case may be).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Stock
Combination Event Adjustment</U>. If at any time and from time to time on or after the Issuance Date there occurs any stock split, stock
dividend, stock combination recapitalization or other similar transaction involving the Common Stock (each, a &ldquo;<U>Stock Combination
Event</U>&rdquo;, and such date thereof, the &ldquo;<U>Stock Combination Event Date</U>&rdquo;) and the Event Market Price is less than
the Exercise Price then in effect (after giving effect to the adjustment in clause 3(a)&nbsp;above), then on the sixteenth (16th) Trading
Day immediately following such Stock Combination Event, the Exercise Price then in effect on such sixteenth (16th) Trading Day (after
giving effect to the adjustment in clause 3(a)&nbsp;above) shall be reduced (but in no event increased) to the Event Market Price. For
the avoidance of doubt, if the adjustment in the immediately preceding sentence would otherwise result in an increase in the Exercise
Price hereunder, no adjustment shall be made. Simultaneously with any adjustment to the Exercise Price pursuant to this Section&nbsp;3(d),
the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately so that
after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of Warrant Shares shall be the same as the
aggregate Exercise Price in effect immediately prior to such adjustment (without regard to any limitations on exercise contained herein);
provided, however, that (i)&nbsp;the adjustment to the number of Warrant Shares pursuant to this Section&nbsp;3(d)&nbsp;shall be limited
to a maximum of 46,511,628 Warrant Shares and (ii)&nbsp;the adjustment of the Exercise Price per Warrant Share pursuant to this Section&nbsp;3(d)&nbsp;shall
not be lower than $0.116 per Warrant Share subject to adjustment for reverse and forward stock splits and the like.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion
of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding shares of Common Stock (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it
is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e)&nbsp;on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company's control,
including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor
Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this
Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given
the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>,
that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders
of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental
Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes
Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of
the day of consummation of the applicable contemplated Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day
immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)&nbsp;the underlying price per
share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per share being offered in cash, if any, plus the
value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii)&nbsp;the highest VWAP during the period
beginning on the Trading Day immediately prior to the public announcement of such Fundamental Transaction and ending on the Trading Day
of the Holder&rsquo;s request pursuant to this Section&nbsp;3(g)&nbsp;and (y)&nbsp;the last VWAP immediately prior to the consummation
of such Fundamental Transaction, (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value
will be made by wire transfer of immediately available funds (or such other consideration) within five Business Days of the Holder&rsquo;s
election (or, if later, on the date of consummation of the Fundamental Transaction). The Company shall cause any successor entity in a
Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(g)&nbsp;pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to
such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of
the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party,
any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation
or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the
Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a record is
to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date
as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled
to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of its Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voluntary
Adjustment By Company</U>. Subject to the rules&nbsp;and regulations of the Trading Market, the Company may at any time during the term
of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any
period of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;4</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to
the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section&nbsp;5</U></FONT><FONT STYLE="font-size: 10pt">.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the
Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if
mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at 373 Inverness Parkway, Suite&nbsp;206, Englewood, Colorado 80112, Attention: Chief Financial
Officer, email address: cfo@aytubio.com, or such other email address or address as the Company may specify for such purposes by
notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in
writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder
at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or
deliveries hereunder shall be deemed given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or
communication is delivered via e-mail at the e-mail address set forth in this Section&nbsp;prior to 5:30 p.m.&nbsp;(New York City
time) on any date, (ii)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via
e-mail at the e-mail address set forth in this Section&nbsp;on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New
York City time) on any Trading Day, (iii)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice is required to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder or the beneficial owner of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="text-transform: uppercase"><B>AYTU BIOPHARMA, inc.</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="text-align: left; width: 3%">&nbsp;</TD><TD STYLE="text-align: justify; width: 47%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"> Name:</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Title: &nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="text-transform: uppercase">AYTU
BIOPHARMA,&nbsp;INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> <FONT STYLE="font-size: 10pt">The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if
any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) </FONT><FONT STYLE="font-size: 10pt">Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"> <FONT STYLE="font-family: Wingdings">&#168;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT> <FONT STYLE="font-size: 10pt">Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature
of Authorized Signatory of Investing Entity</I></FONT>: ______________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ____________________________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; width: 34%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 4%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>tm2222304d3_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">August&nbsp;10, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioPharma,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">373 Inverness Parkway, Suite&nbsp;206</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Englewood, Colorado 80112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Re:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Registration
Statement on Form&nbsp;S-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as counsel to
Aytu BioPharma,&nbsp;Inc., a Delaware corporation (the &ldquo;Corporation&rdquo;), in connection with the filing by the Corporation with
the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) of a prospectus supplement dated August&nbsp;10, 2022 (the &ldquo;Prospectus
Supplement&rdquo;), to the prospectus effective October&nbsp;7, 2021 (together with the Prospectus Supplement, the &ldquo;Prospectus&rdquo;)
included in the Registration Statement on Form&nbsp;S-3 SEC File No.&nbsp;333-259862 (the &ldquo;Registration Statement&rdquo;) filed
by the Corporation with the Commission under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), relating to the
offer and sale by the Corporation (i)&nbsp;21,505,814 shares of common stock, par value $0.0001 per share, of the Company (the &ldquo;Offered
Shares&rdquo;), and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the &ldquo;Pre-Funded Warrants&rdquo;)
to purchase 1,750,000 shares of common stock (the &ldquo;Pre-Funded Warrant Shares&rdquo;) and (ii)&nbsp;warrants to purchase an aggregate
of 23,255,814 shares of the common stock of the Company (the &ldquo;Common Warrant Shares&rdquo;) with an exercise price equal to $0.43
per share (the &ldquo;Common Warrants&rdquo;), pursuant to the Underwriting Agreement, dated August&nbsp;9, 2022, by and between the Corporation
and Cantor Fitzgerald&nbsp;&amp; Co. and Canaccord Genuity LLC, as representatives of the several underwriters identified therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have examined such documents
and have reviewed such questions of law as we have considered necessary or appropriate for the purposes of our opinions set forth below.
In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted to us as originals, the genuineness
of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal
capacity for all purposes relevant hereto of all natural persons, and with respect to all parties to agreements or instruments relevant
hereto other than the Company, that such parties had the requisite power and authority (corporate or otherwise) to execute, deliver and
perform such agreements or instruments, that such agreements or instruments have been duly authorized by all requisite action (corporate
or otherwise), executed and delivered by such parties and that such agreements or instruments are the valid, binding and enforceable obligations
of such parties. As to questions of fact material to our opinions, we have relied upon certificates or comparable documents of officers
and other representatives of the Corporation and of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioPharma,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August&nbsp;10, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the foregoing, we
are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The shares of common stock, when issued and delivered against payment therefor as described in the Underwriting
Agreement, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The Common Warrants and Pre-Funded Warrants, when issued and delivered against payment therefor as described
in the Underwriting Agreement, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance
with their terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">The Common Warrant Shares and Pre-Funded Warrant Shares, when issued upon exercise of the Common Warrants
and Pre-Funded Warrants in accordance with the terms thereof and the Company&rsquo;s Certificate of Incorporation (the &ldquo;Certificate
of Incorporation&rdquo;), including, without limitation, the payment in full of applicable consideration, will be validly issued, fully
paid and non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify">Our opinions set forth above are subject to the effect of any applicable bankruptcy, insolvency, reorganization,
moratorium or similar law relating to or affecting creditors&rsquo; rights generally (including, without limitation, fraudulent conveyance
laws).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify">Our opinions set forth above are subject to the effect of general principles of equity, including, without
limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance
or injunctive relief, regardless of whether considered in a proceeding in equity or at law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify">Our opinions set forth above are subject to limitations regarding the availability of indemnification
and contribution where such indemnification or contribution may be limited by applicable law or the application of principles of public
policy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify">For purposes of our opinions set forth above, we have assumed that the Common Warrants and Pre-Funded
Warrants will be exercised by the holders thereof immediately following the issuance thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify">We express no opinion as to the enforceability of (i)&nbsp;provisions that relate to choice of law, forum
selection or submission to jurisdiction (including, without limitation, any express or implied waiver of any objection to venue in any
court or of any objection that a court is an inconvenient forum) to the extent that the validity, binding effect or enforceability of
any such provision is to be determined by any court other than a state court of the State of New York, (ii)&nbsp;waivers by the Company
of any statutory or constitutional rights or remedies, (iii)&nbsp;terms which excuse any person or entity from liability for, or require
the Company to indemnify such person or entity against, such person&rsquo;s or entity&rsquo;s negligence or willful misconduct or (iv)&nbsp;obligations
to pay any prepayment premium, default interest rate, early termination fee or other form of liquidated damages, if the payment of such
premium, interest rate, fee or damages may be construed as unreasonable in relation to actual damages or disproportionate to actual damages
suffered as a result of such prepayment, default or termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioPharma,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August&nbsp;10, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">We draw your attention to the fact that, under certain circumstances,
the enforceability of terms to the effect that provisions may not be waived or modified except in writing may be limited.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our opinions expressed above
are limited to the laws of the State of New York and the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion as an exhibit to a Current Report on Form&nbsp;8-K to be filed by the Corporation with the Commission on the date hereof,
which Current Report on Form&nbsp;8-K will be incorporated by reference into the Registration Statement, and to the reference to our firm
under the heading &ldquo;Legal Matters&rdquo; in the Prospectus Supplement. In giving this consent, we do not admit that we are within
the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations of the
Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Dorsey&nbsp;&amp; Whitney LLP</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NST/AWE/AJM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>tm2222304d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 376.25pt; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2222304d3_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aytu BioPharma Announces Launch of Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in"><B>ENGLEWOOD,
CO, August&nbsp;8, 2022 </B>- Aytu BioPharma,&nbsp;Inc. (the &ldquo;Company&rdquo; or &ldquo;Aytu&rdquo;) (Nasdaq: AYTU), a pharmaceutical
company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of
shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of
its common stock, and accompanying warrants to purchase its common stock (the &quot;Offering&quot;). All of the securities in the Offering
will be sold by Aytu. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the
Offering may be completed or as to the actual size or terms of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">The Company
intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt
Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS), for growth of the company&rsquo;s commercial business,
and for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">Cantor and Canaccord
Genuity are acting as the joint bookrunners for the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">The Offering
will be made only by means of a prospectus supplement and accompanying prospectus forming part of a shelf registration statement on Form&nbsp;S-3
(File No.&nbsp;333-259862) that was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on October&nbsp;7,
2021. Copies of the prospectus supplement and the accompanying prospectus relating to and describing this Offering may be obtained, when
available, by contacting Cantor Fitzgerald&nbsp;&amp; Co., Attention: <FONT STYLE="font-size: 10pt">Capital Markets, 499 Park Avenue,
4th Floor, New York, NY 10022</FONT>, or by email at prospectus@cantor.com or <FONT STYLE="font-size: 10pt">by contacting Canaccord Genuity
LLC, Attention: Syndicate Department, 99 High Street, Suite&nbsp;1200, Boston, MA 02110 or by email at </FONT>prospectus@cgf.com. These
documents may also be obtained for free on the SEC's website located at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">This press release
does not constitute an offer to sell or the solicitation of an offer to buy any securities in the Offering. There shall not be any sale
of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>About Aytu BioPharma,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">Aytu BioPharma
is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics
pipeline focused on treating rare, pediatric-onset disorders. The company's prescription products include Adzenys XR-ODT&reg; (amphetamine)
extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT&reg; (methylphenidate)
extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention
deficit hyperactivity disorder (ADHD), as well as Karbinal&reg; ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine)
suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor&reg; and Tri-Vi-Flor&reg;, two complementary fluoride-based
prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children
with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKC&beta; inhibitor in
development for the treatment of vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood
resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has
received Orphan Drug designation from the U.S. Food and Drug Administration and the European Medicines Agency. Aytu is also researching
and advancing the development of the Healight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device
with potential application in the treatment of severe, difficult-to-treat respiratory infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Safe Harbor Statement Under the
Private Securities Litigation Reform Act of 1995</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">This press release
contains &quot;forward-looking statements&quot; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as &quot;anticipates,&quot; &quot;believes,&quot;
 &quot;continue,&quot; &quot;estimates,&quot; &quot;expects,&quot; &quot;intends,&quot; &quot;may,&quot; &quot;might,&quot; &quot;plans,&quot;
 &quot;predicts,&quot; &quot;projects,&quot; &quot;should,&quot; &quot;targets,&quot; &quot;will,&quot; or the negative of these terms
and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding
the anticipated closing of the Offering and the expected uses of the proceeds from the Offering. Completion of the Offering is subject
to numerous factors, many of which are beyond Aytu's control, including, without limitation, market conditions, failure of customary
closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included
in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any
forward-looking statements made by Aytu's management, which are based only on information currently available to it when, and speak only
as of the date, such statement is made. Aytu does not assume any obligation to publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise
required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Contact:</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark Oki</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">moki@aytubio.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Robert Blum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lytham Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">blum@lythampartners.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>tm2222304d3_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 376.25pt; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2222304d3_ex99-2img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aytu BioPharma Announces Pricing of Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in"><B>ENGLEWOOD,
CO, August&nbsp;9, 2022 </B>- Aytu BioPharma,&nbsp;Inc. (the &quot;Company&quot; or &quot;Aytu&quot;) (Nasdaq: AYTU), a pharmaceutical
company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering
of (i)&nbsp;21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants
to purchase 1,750,000 shares of its common stock, and (ii)&nbsp;accompanying warrants (the &quot;Common Warrants&quot;) to purchase 23,255,814
shares of its common stock (the &quot;Offering&quot;). The shares of common stock (or pre-funded warrants) and the accompanying Common
Warrants will be issued separately but can only be purchased together in this Offering. The combined public offering price for each share
of common stock and accompanying Common Warrant is $0.43, and the combined offering price for each pre-funded warrant and accompanying
Common Warrant is $0.429, which equals the public offering price per share of the common stock and accompanying Common Warrant, less the
$0.001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the Offering are expected to be approximately
$10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Aytu. All of the securities
in the Offering will be sold by Aytu. The Offering is expected to close on August&nbsp;11, 2022, subject to the satisfaction of customary
closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">The Company intends
to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial
evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS), for growth of the company&rsquo;s commercial business, and
for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">Cantor and Canaccord
Genuity are acting as the joint bookrunners for the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">The Offering
will be made only by means of a prospectus supplement and accompanying prospectus forming part of a shelf registration statement on Form&nbsp;S-3
(File No.&nbsp;333-259862) that was declared effective by the Securities and Exchange Commission (the &quot;SEC&quot;) on October&nbsp;7,
2021. A preliminary prospectus supplement relating to and describing the terms of the Offering was filed with the SEC on August&nbsp;8,
2022. The final prospectus supplement relating to the Offering will be filed with the SEC. Copies of the prospectus supplement and the
accompanying prospectus relating to and describing this Offering may be obtained, when available, by contacting Cantor Fitzgerald&nbsp;&amp;
Co., Attention: <FONT STYLE="font-size: 10pt">Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022</FONT>, or by email at prospectus@cantor.com
or <FONT STYLE="font-size: 10pt">by contacting Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, Suite&nbsp;1200,
Boston, MA 02110 or by email at </FONT>prospectus@cgf.com. These documents may also be obtained for free on the SEC's website located
at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">This press release
does not constitute an offer to sell or the solicitation of an offer to buy any securities in the Offering. There shall not be any sale
of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>About Aytu BioPharma,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">Aytu BioPharma
is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics
pipeline focused on treating rare, pediatric-onset disorders. The company's prescription products include Adzenys XR-ODT&reg; (amphetamine)
extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT&reg; (methylphenidate)
extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention
deficit hyperactivity disorder (ADHD), as well as Karbinal&reg; ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine)
suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor&reg; and Tri-Vi-Flor&reg;, two complementary fluoride-based
prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with
fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKC&beta; inhibitor in development
for the treatment of vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting
in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received
Orphan Drug designation from the U.S. Food and Drug Administration and the European Medicines Agency. Aytu is also researching and advancing
the development of the Healight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device with potential
application in the treatment of severe, difficult-to-treat respiratory infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>Safe Harbor Statement Under the
Private Securities Litigation Reform Act of 1995</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">This press release
contains &quot;forward-looking statements&quot; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as &quot;anticipates,&quot; &quot;believes,&quot;
 &quot;continue,&quot; &quot;estimates,&quot; &quot;expects,&quot; &quot;intends,&quot; &quot;may,&quot; &quot;might,&quot; &quot;plans,&quot;
 &quot;predicts,&quot; &quot;projects,&quot; &quot;should,&quot; &quot;targets,&quot; &quot;will,&quot; or the negative of these terms
and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding
the anticipated closing of the Offering and the expected uses of the proceeds from the Offering. Completion of the Offering is subject
to numerous factors, many of which are beyond Aytu's control, including, without limitation, market conditions, failure of customary closing
conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration
statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements
made by Aytu's management, which are based only on information currently available to it when, and speak only as of the date, such statement
is made. Aytu does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a
result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Contact:</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark Oki</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">moki@aytubio.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">Robert Blum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lytham Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">blum@lythampartners.com</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>aytu-20220808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaGHObOdzZR++YkxtmB9bckKryQq8g13PyV5RUamMUMH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:AYTU="http://aytubio.com/20220808" elementFormDefault="qualified" targetNamespace="http://aytubio.com/20220808">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://aytubio.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20220808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aytu-20220808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>aytu-20220808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>aytu-20220808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aytubio.com/role/Cover" xlink:href="aytu-20220808.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aytubio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2222304d3_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2222304d3_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Z *H# 2(  A$! Q$!_\0
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MBO-=9U>^\;^.9M9BTF[U.QMY5"6\*,<0C[JG .,GD_6O2%^*OBA45%^']ZH
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JM,$&7\L87-;-% &%;^'+6VDMIXWE^T0N7:4N3O)SNR,X&<]JW:** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2222304d3_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2222304d3_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X *D# 2(  A$! Q$!_\0
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M,NQL</1G??H=Y96D5E9Q6\"8BB4*J],"N!\2?"E_%?BU=9U'67:W5E"VJQ#
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<@.?Y\T44 3+;QK<FXV#S2NTMWQUP:FHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140343156737232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AYTU
BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001385818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-0883144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">373
Inverness Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Englewood<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">437-6580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AYTU<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>tm2222304d3_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aytu-20220808.xsd" xlink:type="simple"/>
    <context id="From2022-08-08to2022-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001385818</identifier>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-08-08to2022-08-08">0001385818</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-08-08to2022-08-08">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-08-08to2022-08-08">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-08-08to2022-08-08">2022-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-08-08to2022-08-08">AYTU BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-08-08to2022-08-08">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-08-08to2022-08-08">001-38247</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-08-08to2022-08-08">47-0883144</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-08-08to2022-08-08">373 Inverness Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-08-08to2022-08-08">Suite 206</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-08-08to2022-08-08">Englewood</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-08-08to2022-08-08">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-08-08to2022-08-08">80112</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-08-08to2022-08-08">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-08-08to2022-08-08">437-6580</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-08-08to2022-08-08">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-08-08to2022-08-08">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-08-08to2022-08-08">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-08-08to2022-08-08">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-08-08to2022-08-08">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-08-08to2022-08-08">AYTU</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-08-08to2022-08-08">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-08-08to2022-08-08">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MFLEPR4Z_\V$BP*N%%9I2];RA6PRV;@ ^ZM\X['PC&V%QR5G!83D"KX<!UAW
MQSW\/>#8CF"MYW(C&N':Y%8IVTB98'!U9_!Q:W\/5U7B5,D7+N+FM<8UQX\8
M6MTL?-SCWZ--I39@-7_Q_/CC@2N&GN]CO<*OFX6/.WVYAA'L9H^CX +]P,-
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M*8L*50=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    "  IBPI5_=A_.NX    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  IBPI5F5R<(Q &
M  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( "F+"E7J#]T89P0  "81   8              " @0T(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  IBPI5GZ ;\+$"
M  #B#   #0              @ &J#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( "F+"E67BKL<P    !,"   +              "  88/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( "F+"E6JQ"(6,P$  "("   /              "
M 6\0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  IBPI5)!Z;HJT   #X
M 0  &@              @ '/$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  IBPI599!YDAD!  #/ P  $P              @ &T
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #^$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2222304d3_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aytubio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2222304d3_8k.htm">tm2222304d3_8k.htm</File>
    <File>aytu-20220808.xsd</File>
    <File>aytu-20220808_lab.xml</File>
    <File>aytu-20220808_pre.xml</File>
    <File>tm2222304d3_ex1-1.htm</File>
    <File>tm2222304d3_ex4-1.htm</File>
    <File>tm2222304d3_ex4-2.htm</File>
    <File>tm2222304d3_ex5-1.htm</File>
    <File>tm2222304d3_ex99-1.htm</File>
    <File>tm2222304d3_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2222304d3_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2222304d3_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aytu-20220808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aytu-20220808_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aytu-20220808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "AYTU",
   "nsuri": "http://aytubio.com/20220808",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2222304d3_8k.htm",
      "contextRef": "From2022-08-08to2022-08-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://aytubio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2222304d3_8k.htm",
      "contextRef": "From2022-08-08to2022-08-08",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aytubio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001104659-22-088699-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-088699-xbrl.zip
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M-4Y)-%U0K #FX%.56N^?EL4C25-YSP#3_H;%)G9-#&Q89\94!D4-: _DIHA
M54A8Z%R^R%&[&#H-+'!#[Q,@PW870[4X6(QTAP-)*L*0C/-(4^.610]'AM(U
M08!5G1U-%A0U=F\@+Z4<%?HP0+FD\2!,:IT?2#2;=D0J48" M)WUX2'4ON&X
M2K((IZ6?*[$MZRBB1>L:$M"N#HHA# H6R!T(3!F@N"E"O$/S3X+Y,&0:2C_
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M,!XF/^>_V"H#'O&;I)XE_XZDU.IU4GU,FX@XX[DMG<F)<P"L&GB0I^5^6<S
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M:--4!5CFZLPU>6HA',V ZD%XXYTT6FF\W< Q-X)ADU+E[WC:= M:R;:RO;'
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M9F=M5AT<=F#.D"!%'3EJMU#'.8#KMIH/A-!DJ(!6C8CZ^%YD X&1OG1/.^^
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M4E"ATF%T?1]D+(FO$> K9,6C7!O30=>"O.;D7">[L,?R/*'..FA>CD>!?;E
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MZY(*1Z%RG9$<S:LG*V$B22$V)Y FUZCA4$D"]8DMSKZ8T6W8H!7Y*Z=)#4K
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M",Q,;ITIBZ-98\E2$1U;<Q&N/&/]VF8L$EKH_$%TE8X(XT-'CU8$97KG$ML
MCRY*-T;%5C'):=_)Z+ISO-1R_ :_2$%#LH7,?G:%M^=0.6O>FE(Q54?H;,QP
M?(6Z3_X2&_?ZX;47XK'KTNZK:8.%HIDS> DKW'%?#HY^>C08+FLW,1T<#!K=
MB!N88R!6IT^'04W>R[0OOE@[I*,E1FGW3346L34LOT-'\S/ORK_]^E).-2,L
M_"&K5ND89!.1<G.C5GI"NN3+5P'=2-_S6/S'(RO_<:]61(<BS:GG,.H::>6@
M9-6M*EI#T2<5M^U(\*"V@\--JT&*!H68PB6#GR==)(*C(6MS*F49X'G8LMF
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M"'RDK??O/UU'AZZ^X:'[UX_N7S^Y?QWRON"C\*>'9I>0R(#AME?=J;(_B&U
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MWW?R6TX!:MZ=R%_A(Z<E#*7 !R4YN4M3ZHHP*6<XC?+\'(_3C&\^:CU4"+)
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MB [@_!V1EIQ-I=,G3OG&],^SL4\SO_WM/0Q_=IJJO@B^2T ]R["LO!1:"V5
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M,+LNZ-$<,\KMV5#8!(@Z:&6;$V?'C!_NJ@]$!?R+;H;ZQ6J^89AVUH-87*S
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M]FLB_([* Q^2J/M&Q,/B K.<G.L3NW4.(0;BTILCF4:._T*\V:XSW8!'@"1
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M6H7=Z$:C""(SB5;T,8Y,PF9< )G#KYW;B*<IN61!.5/,V8J3(B]P1W<\$,*
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M*=DGK(LBF^>U@,.EN?T5+A!LIN0D9RD<4J+]7%CNS6HFIU[0V8_'<=HXYK!
MQ-:&^'/B8)*N!]#@AD;\^%*)&VOW>T 5M99/25)B@@JEA-N().CHME.X%BKO
MU#GB^C5C\?!>S(2KH_O[:"[ 18:O)PC8X_E*G>IUKG;@="X?0X)=)B(,D6&,
M4Y4,'#F*OG;8P)W/SCDMJ=?F'@.F9B/P K//V-85)5Y"N>5"@Q;>0.2"6KPS
M',7B[)!+ZKE;^5"_9U(CY)W\,K>HP</P\&=<K9IR>_$(4OTBV$W,+'.1AYNI
M8Q[/T'E( TF,M+>]#.\LA8=F#+Q.4PD 4- [C#U<!];AU]C M/9?@S[G98S=
M[F=K255[1F'KR5#=3PL/"8 EY"K:L-+7W<0G8!$W$'>!C61S/E^ME+KHI\),
M&:R3_:QI+IV].1M#NB#77%[EE-7$8_T=#(\ LS<A1K?83GRQ0>L9<X=M!W&:
M3VN!"$Y0IFO6IZ$O-1<B^-6TGM>"^R2(FMA%!E/T2I FU(GLKN#=IX2@&LO<
M,'*G8SY!#K )FEIYUL9QJQ2QG.)<%?,*Q!8"^;OK$OFK*8=!_7V;(SJB2 @R
M5.H% )_;7N)_OOO?+F:T#SWD$ZVH?][N)%R12D?#W0<HE4[E(^K.G5N&I(,N
M!HZ:3\/GQK(GTI4=&,JYLM:!?%.99EGHLK$UHGC)/F,KIHHBR::1UA_,*7[O
MUBE^PT[Q>[=.\6VY,]?@%#R_4:?X7[5:[V*.1H<++138Y'[O]U%:TIA'&*IN
M ?(J+C^IVA<SR$7=\AO+TBD<WT2G V$[E[81E!8W$O$2.)@T?!>G/N+$=-\X
M$13X7AJ0W>1.QJ5.A!H6F/@"SW$"?2$86<[LMY^M7QM8[L,M \O5#79<Q^!W
MY,O^CL!RUSX*$&"99&#N]7MG8>8*:7ILM-DDKI7E(N3I0<M<$EGY#;MLZYF!
MT: @;UZ1"4X_N6D&IOX >48+;+S.4P1&D&,I/3IIQNE(A6XIR<I#E/SSG)NE
MG7,=G-\3T29LFEHY<I[Y>)N>9T@,%$Z)JNL8NUQ&DB>2S+E*?#2O&_F:,B6:
M!RGY(('+7'$2QWB.:,75'!>3BC-]AC"UQ'>UY57'GQU\7^,1F7+.G%:A]>.2
ME,49;69#8S33T[$QC'2A>KR00L&&B2'KX:P;;<O%40Z71^\0+.>C-NIE?S #
MQ3B5:',56WWR<T7Q5>N$&>AN4VS]"<"KADQV?@<FW[3BG)Q1].@YA8\61I11
MYK3WAQXIPH5(2JJ6<%T]#\'6@%D4>C&)SI5J@+3JR PWR04],,L0J?5U42/]
MV3!OOL!^7.>ZAX1-YX/#+!<M=3^"+Z%/D1SQL\FB0A49$_C,>7N3\MN,1/,\
M0V^;\W(L1M2+"G(.<R!2S!0VB=_M #&P+VN-+1W(ZDD)=+'S0!P^3C,RHYWX
M[C1G/*%%#"RY]Q=OILFO-RE6]'G81TNOBFU<4V65CFU+#;,;?J*X[D [T&U'
M+/X")3,C44TDB=OQ].GRUC TIEGI)*:Z(9\H.2;_0PK*:P6DW33DI2X-?KD@
M;GDR4_>?2=E3Q- A0_)I<BDXR1W#)XE]2V]H9G3BZ=)XT&C'57&:M(LXS)SM
MD&7:-TU<<F&:8,93B<%ZW-3>9X?D7-<L4Q^(";X&S?;GK5+-LT)&R_I3/]R)
M=P=.RU,C[;RN/A32N' XOD9RMONL ;<Z)5BTM@ +RAI4ZW/BN6XY;BR%#ONO
M>LY&S&2RXW'*#0IS67KEUAM7UDN<:%0L&"%%=<0B>EG_6)BC:MLMX[U#^:#3
M4ITGK=?,B^*W<"I3B6:=B*S\_)#\Z5K1 #?D3W)0_9Z.C&D>%5Z'4D?._-IB
M8D@<F-#$C6Y>:6850"SPQ8AK$[X*RKQ:)V.+GUN41 F):$6$>2&E[C-$=T'_
M^NM!YH#^ 5:_2A7K8A$>4R6FD*IQ-5CMB8<4'%6,JF5&;8;FO/([>4S',%K@
M[MSFY>37P'!R3=VZ=?+@  >GI)I1/:<\!-?SK56_[;]5:SJF[]\ZIF_8,7W_
MUC&]+7?FVKQ^C[;,Z_<JK=#FY?CDK;OOAE+U3#L-D'KO;3)7](&0!+5C'E@&
MMLVH:^Y.B3+Z**XF+99.4BA.+I$(L&L1B!8O*"HZOTQGB%0.'$UIYA2[*68=
ME5@Z/.^+8/BR#>4V42*2W9T4M VKW;:&@,/O/=B+/KJN3?'0F P6VX?=[683
MZ,E87*KU(4S+($^+GKZN6M0Z-+DK@KF/-,*%-PIE>(BS;DG#$UFZC?JT?*J1
MB=CGQ !.I@DR:XKN.;@Y?C!<#MM'DZF(8KS:X$#9^B'O_,VVTGE95)B" KKR
M&#3[8X7>T9'VIKX"534S.9AN+,93KD<%4 );NJCH:_- I;!7(>#:V!3S=Y41
M$XE;+-,,)X@_X?P2?WY3;WZ>VBXJ-^>TCE#SHNPE71]NJVC]VVB<R^BS)&/
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M],OAF^._4V3XQ=FKE\_^/U!+ P04    "  IBPI5+R-?EW1>   N*@( %0
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MBVAO.6GEHJD;6$"<*UQ',+=!!\"&@9' %,\;W#O&,!#K.$8[$]XS3=F]23_
M:%%(P1/X8%O+<YYD5L+)K[]A35 F%<K;:?2"U'99:2,_8H5/XA8OQ-F:F.O4
MUMOQ.;KC[+3_=?=N]'.6YI/'T5LXET_@>E -Q1@-SB=PJ.DX/L;[BL'W)/H=
MSP-\'=V]*QF/GUZ\_-W/,]QMRCE<<F]NDQ-W1V73E+/'T2/\;%16L-/M9\_R
M!,[1$8RM+O-L N,[.W[VZB1Z?O+JU=OC%R]>OOZ/O]XYO$-_G[X]?F[^EF?*
MW<:@<9-Y#6,S_WH27663Y@*GZ/#/78[ V3MSCTL,,HR3W.P7> %_ ^7IE'[Q
MPOQ";GW__I_= IV]Z+KBP9][XOMJ]LV\/XG.EG,8X'&5C++QD^AU,DMY;5Z7
M..-'^D??F5_A-WU/O__GSI2/'O)W9^_P_^&<PW]A-3L6=@1BY?W=40JZ 08T
MI\VB%_M1QUKC!H#7;">AYHW>U-XC]>OA:_,VV\5C]*FB9E&#PJCKX0#LG+:0
M89-S*;H);$=0-TFSJ. S& [8Z DY!/PU_6%,,G0-,#Z0@/A.BO?HO5$L@HP@
M$%+6*D)EEBR:"] S_Q0KLX(-!0*-!'Z>7*'6J-)9 G<8YR48:$\B&/F\*B^S
M23K!0<?XP45YE5YR0(WM93!Y8;[09<S0&VF-B)4+&BLC-*13\(#P4:-KCR>:
M+$BUR;2"'EQB8.VBG*4RG;'][B+-X=C!@MR=@[QI?5^4Q5U8#HP"PCC3V3PO
MEZFYBK<.#0D7AF?=&3BLMG&XX%=EQHAA(PH'NF"S 7\ZOUC6*&BB$:AP6*V\
M'$L<,6DX]D<*A6PE_L5Y"7-;8%P*?B7STRS!F"CAQZCS62.1:5&5139&0VI2
M1YPLQ'$NP18$-W O*\;Y@NP$7*2K#"TZN:BF -;&6P=,.+!]\QR&02816G]X
M3W!T<*G&< 1@"2H*CHK]N\L:\1./,IJ#65UG&$%MA0=P;7XK,K3Z3ALP\VOM
M5J/M=?)A#*?[G(U6OLVW/576,.\VK22T49-Q[1M5,2@>$_S_T^'!X>&1,_UC
MFDQW.D$&U624U6ZZP9 NC7T+NQ(-<OO=#$2'C56C*()CB+? U ,Y4KQ*DW^1
MM8E.0/+"3,.E'28P3K.:.W^5C.0[78SJ3$);,NM7Y2*?F$P+771!3@^G"? V
M)3@M)/-!LJ@,B?:X"-W @BR.,/ %'I#*R,2L.],1N.W@88-P0P52\R_)^@$G
M<,Y77DF<W6K2C")CE 2@>$U6^^,8EP69BNA2T6Z"7TKVA]PL^I-W"OT-0C&V
M=[_"F+V\?-WS]I+3BOUDPC>\Y^Q\PL:S.ZIGQ[%(,&LE&W 9[2DC27R6?;-\
M7IX-)02'-_&C<5:-%S/TG<?X=B902UK>Q6WCUIK'&ZTX;_B-UUUV/6]>SE"1
M'_JOL0U !\*!1J/O95TO<$&Z=4,FWZ+$L1%4R>>%<1G<)[P9<'Z-00?C+Z=@
MFHK%UN>^4UH2GT4I7W_ST4TC,"(+,#\QRC*!CR3$1L8._'0.UBGMG'J1-Q2K
M"61D>/OT0U93N"MX#@QD@P?AY?:M5CT(-_9BG)* "]_HG$2AOOYU4D^2?T2O
M>&C#@4L4/'QT_^'>>'_OP3Y*XRA-T/' 1"='+,%#D%B8"V3)N,C.EL6 E<48
ML!WS,Q-5>>&6I6K? TTK^[N$#(:L:5+:%=[MW>J"80ZG,P,GH#U]_$%:75+P
ML\*P7<4.B9K')RYN[!3?<&"A A8"H.0!Y7LKD1^U,NFU20([&AYF,\XHH[X+
M11Q>N$+F$*; /4EIIYZC(0\EI("*'LJK4*R:9EIG"HW7QX*5YD^-#G.&PP%[
M=. +)#.<1="Z&1[6OIM2X+<88\"2+RH6N*QDM 7W9QS#)%47VQF?<Q;<S(B-
MQWLS;V/TX9VU\L@HHU:(_T4Y-3XD]3S'"#7=<C82T /Z3#0L$&VI #\P#FR>
MHLU+%;M'" 3%;2R:A!-'25%D.-JDLF>E>R6"W4,[PN[#<@Q?5JG(2++&W K#
MP<E !364@H3C<"ZNIR<CSJN4Y ,A8N@DT%;R0\ .6]*[N#K0WMKP@7Q%Y5=G
MUF\&&PSN> ZN+/FGB7C4JP7+!.X@@7(,#/0(]F CPQH%^P']67,^:A,<,(X]
M;FE[J5%/>S[^P@G)HP</&(XSABE9@F@"X7*>T<OA_B);M)9A2*2#8#N82VAD
M9^1T,'DEO5_7Z$R2'/=W+=D4M'4G,$[,KL!]?CQ$#[S6J?Z^[07V;C$)3CO)
M+)PGJW\Y@E,6H)5&%($QN6=.<O&VP%=JEA<ZK<$7[8MUE,&Y@'.5YE/V&3A!
MCB>M5KX##0EC#/CFF%!U;@9^?E6PR(!_@[N6TGPDT4C":U&]A.]QWF WT;10
M^-Y\&RA+@GK1J\D$!%H 44*,M, 025K JC<4)0D!&!D('@$3P2,H(!,3)LJ%
MOMB) 8VI-SG>R\NLTK R/C9D'BCE V<0C+ ,UL!D[(Q&PP1:@N<!9BN99Q@Y
MXF6!22)#= E/*5EVSE#@V G!1]'8\;<P&/>\';8^-\MHW+M-7FPW>7'O-GFQ
M*R?FH_RUCT8"*T?O,L4"#8&1A*";2# W)*=!Y\X%<HLRD"W7Y\[\BNA>A#R-
M(P&@H0Q$P$.&W_A9^4D&\AR%VMX',4K(DZ@7,Z,$?O_C^&TOBH,\'(/M 3LM
MVGLHMP&%BKEYA5JIM>IMKF LRVCOWN$^^8,@3QO\O4:Y@&K+2K")4I?%=[%Z
MA;^AB[,9 <::-%\J! E>56=@B,+3+J*]HT?-Q;[W,T$@HQ9?/94T46BAP:3M
M+>4ES2L?1,>@OCBD+],K-J0%#)"5!GJ%1\BH6O&ZG!_-#RDFL3:PS1_*QH[1
M,A(5IC D?@)&ZT^9>?;O:%IW6&]]>M1$/)[C<=,=,%&Y!IMG@(MQ)Q_]>/\!
M(07%68LM>KT""[;F5V5 R?DB-YY"5<X6^3EA01OKM'Z[4RSAQ![8)UOP-HQ<
M!S$G'^R.EKV!@_>'K%1 5"W>MSO![!!TSB\%84%,+-AZ59A_R@,U8-?7%]D\
MAO,/SZ*L@%S""9M%X7T"SD$YSN3W?R_!5XQ0ZBTPZ$K9 [@FS\!RR=$\'EN@
M%%]J)1,[D2XI2PX/^AX,:Z/8T@C'75MOK)SN.Z$EYK>X=._A';_=Q7VG'%;,
M*XG'VBVJQ-GY2U53NK[/VX4_?BZK&;_HZ=W[T=[/&9R5UZ6@/N_?OW_WWH,?
M[GW_XRX7/GSBQ)XJ+W 3V>]$_OU;D;]N;DWH8=DC]6UL8MD;/@"50/46&KR;
MY'7IG'Y,45*(2E<)K+@U5GT+*$9219/N@K%O=V$L"+T;,.6CH#J!Z7"#;@S]
MO\"D\8MV)U9;-0N,?:YUHJ%>/;?K .=FEPX'JOS@,7W\^F^G)]'Q#-Y]C'-!
M'W'BZ;G$KC0*7[[ZC[P<K?SFE !1_@4&OB2 >6,1QR$<?L_X*HA1![.AJHT7
M:F<*)"38!>??G(ZY 1__3#!EH)K..[4]YGA!<'&2#W:2LNL( $0)C,8!V-"T
M:EIQ?"EYFB4<(T\FDTHBNA(,>%.DL!G2XJI$W_H8016G"S#S)#A_>'@41^^2
M',LYXNCU\^C>]X\.[PN**$*48:YNZLW+N,S+ZG'T;T?3!S]^/R$&#K-VEG(C
M*Z;EOU,BH6+A?@#&HT37O;VU^CUW>']M%G6]?QMUW6[4]?YMU'573LPGZG(,
M4'[%)8J3!%-5/55T:XH7-RZB@Y%X)8O1UBH60=2O+$7\8A6+P\'GFNQK52QR
MR5DX]5NH6!P.PI+%:!L5B\-!1\EB],4K%BG.WU>R&*VN6+RXZ8I%.#.])8O1
M;<5BATXP,]M9>:#0.(3UHEWC;04;D;8A;,&^!'"?3-!%4[!3!1E@Q*EZR%5B
M?K_#$[X3G"/WOBK.$4,X0X0CWR;7Q\TM=;+_.59LXS4BU+CBT3IP=$$BC.V9
M%P ::!J0U>AAR+%7)QJK8D"DSI))&O.A+QE_"O_&'$S 8U71?S%4Q)%*&Z#L
MI*U25%7L);#A%M!*4?(^S1$;N0QTPCYK'@)'IQ\PLXYV0S(F18[%&G-&\[]]
M\3/]@?%5@@K3BZ9WR<='W2__3)HF&5]@FF'?3-;KLA%3R0Y=9"%&9!&T"0]F
M_"Z,+>"B:O]84T8=# =_@#*5VX&%!68W(=GV,H-0N();WI,_/( !SMQ>ECDD
M@\+.>A=BQJIB)!CE!%#O(LCZ-&V:G#,J;P5]L+>21VJR;X?%E&;[/6A"1X8&
MP\15K4$?L_9FA@/1U+*F]$5R?EZEF&*(W#8F<(BU["1CBI 0KLB2:7/&9M=2
MP2I[98Z41TSJ"YAHFV<:7Z0(2*B2JX*M>:]:#\RCI$!RKASC0!2>@M_3'PJ
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M^GGG$<QA0N83>_5CE=;].MB\-T@)/+A-"6PW)?#@-B6P*R=FR\[J:-O.JH6
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M[(S]Z/NWZJC^<.NH;M=1_>'64=V5$[-E4K!T.Z1@?B!3.46O;+2Q0QR[E+Z
M/_'#7EG*9D*;KKB-<S"W8-)D+Q6B[]</P/"RD+$1W;!PU@+E/*@$TF7TQENT
M1CM?I$93(^H6C8WFP@!=5]*<>(42>TUYGI(Y:_-30?SX&(R^',/P=6Q)8-D
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MF?D7[-7^,U:N4MEF+_Q]'0XYQ*Y81RY0BD9PMC4<\P9UI;;N[XWW62-'KE&
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MD,FGC6J5VW.?($]D;GNMUX[ZWAJ$K'FAL/12!6+<NP:-?3<;LID .BQ)5KF
M?OLFE"*A&.P5OFC78X2PB^P#%@$YM?#";56K&!<21+IVW/[H-QHXE\IQUMC-
MGWZ;!#Z[F*4-"K9+[@@OX@7%<>VP4CH#11K>U)_TB=_:KW-WX0'M;=.XY\U-
M; 4C)(GCS(RN*(N[]:*Z%((]K.)?4I"T'4];1K.4.#GLK'L@!H[^A/<*]Y2_
M*AL<H([=%'1[IR-6UZF4-(X6-7*"K'Q##&N0[F<Z I,X:^5>8@_CVC/%>^W
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M0FJ?9'>*8E5/M(U=X\8!98$/]ER3Z#D#DD&@(NX23]K/,$0^?S_<_;^<Y/:
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M,<!B3I$6 \M4-GEI+_VXX4O32C:DB?/<P-HMP5,B14J"!1ZAR#(C$F8LTUK
M4ZXR2I._D2KKVJ'<1<*:C.AE5N:><%:E)7ER1:V^+=PN9C=/I#C+[YDF#?=A
M>#Q7/9T[9(0Y1L$F*RW1Q*5MY/60SE9GJ?@M-UZ9*I4$H(D9>GPIF(3OX&1:
M>9OA(+P/\_HN3<:\<Y'Z4MZ8<T*DBSO5,5<+(#Q&\H*XV9>&=A8;ZA58#%8+
M^Q7%]##SSVPYM-$^H$0#@ZS@="0?@SH:$^-C*WCJT]X;89":FH9HCYU];-\A
MN!G_%SZRALF"N$$#L5J6E87]NSP=/6%_AV7_AJFL'V]365M.9?UXF\K:E3-S
M'7M)[-43B>L5AED+*V.HM@D4V55"U-=<KB1"'#-!&B#1!;,C9V*I_!/5V+<'
M:SD3VE8T(Y2ORFVQBZ!#37-1E8MS4U#L]U[R:GJE9K>GZL\KBF61B]J#BH.G
MJF".,""N&-U5U5HRO\LRFW X(WU/)@-]@!-3CM!\-#W@P.ZDNB[%Y"82']'Q
M+:(T4$\+,4-9-W-[")+_YR48L-.$<#%U#9K=!4>JBB Q.,=2V,Q@2GJ$@B8J
M3])<8[J0=9E"[)$:@#S#])ACC[-L-K1K:GF#P+*OL\^Q^@UI]T"O5D3CT(X8
MXVW/TR*MDEP5[^%Y/R]I*S6ZTI[FR49L)0Z$9IX$@I+*:\G2(J08E=)M2@H&
M##B5U##:%1NWCQ(<ISR< <'\;*\=H6>/&O;$M1-/+="JB>DO$%9?B/'"=DF>
MGC/0ES;W*CMF0],[L+I4JT$L^::BO6K,X&)G8(-(F>(N(+^'.<+5>XOAE4@M
M,#QO)HWBG=RI#17ATO 9BZ&,(<)1.5D:M.'?X<C6DVSL]T[@246NP]@W[=/"
MK+"=0]S5?$K9I5'$MQU>QN[:3Q^A"YY)LW06"V15RJYD%R!L^(U855=79'+X
M?;"JS3ILN=)>OYBG$_6V>B\QQ,SN)KL;]+829%?<>>[Z]QQL)=QT<"?X+VJ(
M%=MOU_?(]B)<Z><DV-HTG?,?(/6K@N*2KY(KCL,B>)$XX6GC8#,FOL1 ,51"
MPU26@^#"DFTA6&<E"PH7O-:F.]WBNFC1  1LC8RL\@")+\EM0]"VC:C08[#=
M7IY<V=C :2-I!%R,OY75>V=U.6YC57R2IZ;WRQ0V>L/4,1B2,'LX.DFHLH):
MJ2(/MXH7D))!4T "O*T9\V>B;D\5EO<7SOEO-?-TO1E"U]_UI26+T-D50OAB
MJEDXR)95QFW&/' RG68Y:M0Z=M5]L0UBQ1RL$X8&D#]XPX*^F*4HX_!%8%SE
M,B43D1'"];Y;6:EAAV$325_-?5--\Z/&L.A/4Z2KQ_#: G5DG3$IEFG])):/
M6<F#X4"MA7#-9%657I9C3I\M1K.LJ5VZ7Q[M"R=#]OR1HXBC9R7-.!GHOR;%
M!=8/.;(2U L31?$CP*CYHM'TU2SL58,A$Y<QW<X<7%H4D;<9Y.5+XH<:+\"6
M@=-C4O'4\+<].^322,Y2-K+0GZ M5(E>PUG,L.+&9E?<]HX-A5(V,Y%30Z(R
MI_:K"?5P#NI:P\FW),XTW[&*+O8_&1\#]C*5<]#<4;D(>D?%95I0J!G^NTA=
M$,S]=NVVX8FQKX!=IB\%DT]WJ264935G:3]G"FX*DT_<_*U\%0KB(9</EXB,
MR[FE\(@NLT1#]E!=LT.83N@GQ%Q"0AL/O&4 (?9VERO'DEWY:M_:Y"+ I/R
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M2?2&6]X]CEXE=?/M1IJ_+/1]H\WPW;,W+_Y&5L\O9[^^>OK_ 5!+ P04
M"  IBPI5P!?*<ID-  # /0  %0   '1M,C(R,C,P-&0S7V5X-2TQ+FAT;>U;
M6U/;2!9^=Y7_0Z]W-T6J9+#QD$F H8I;9MAE$BJPDYK'MM2V.Y'5FFX)X_SZ
M_4Y?)-G8A$Q(ANPF#P'+K3Z7_LZ]V?_EZM?S@W9K_Y?3PQ/\9/1O_^KLZOST
M8'_+_<2W6_[K_:/7)[^SRZO?ST]_ZHQ45NRR?B\OV)6<"L->B1E[HZ8\B]R#
MB%T*+4<=O(A7+\)[4Z[',MMEO<[!DVQH\KW]K8NE)??=>H]5FV%I;X\5XJ;H
M\E2.\4C+\:3H'.P?'9S>3.10%H[:SF9_?^OHX,&(?ATI#LMQ:;P$_5[$MGO;
MVX]7!/ [+TIV)-7%A.LIC]S^9UF\^8 T!C\.V%EV+70FC&$77+^?\3D6E[(0
MCN!V[]D#TCO-QJF8*95$[%BE2O-$L>>]?O\1'X3'DLP20>_W-G=DUCEX(W:?
M_/WY]N#%WI_]\4:,I2DT+Z3*VJW+@A=B"@I,9>RETE,GQ65W\'@UTSDXYXG$
M<IXE[&?PGI($NX^7X46W\ [>0([FJ\_WK6 3?BT8CPN1,&Y8K,K,B)05JMU:
M:YD1X^Q$I'S&M< ;.E?N?-E&,1'L29K\4:J]X_KY$VV?/(V8S+ ^RT1LE\]D
M,6'TRDBF,ANSX=Q^:KQIE[1;]/12Q*6613B(TYMXPK,QK9Y.I3&WR8?'@3I3
M(_"=:V5RT"\-,V6>IPZ-"2?Y5[G.A4TOJI<!Y>KM6KQ"60$:-,1H1,)"Q:_C
M0@V%=KO_:#?O8W,U%GA%U[JH:;":1,16<A$HMULRB],R@0S0,"UMFAU;;W7L
M\O28O92I8*_4IGLZ& RZVSLOGC];%'WUAI5N<8(B:;?6G*!_6!U4"11JMG2J
MAW%!1]1_,1A$!$4. B11DXO%Y;7B-=!8$(3<";1;"GK7%BB&0[H5?&W(I][U
M]Z.=WD[TO/\#,T ZM@87,9C%(E.H^'W$<J[9-4]+P?[1V^SU>GV68W>[.J+5
M7KR<9_,%=E\3%Z272[MQS2\8L\:02E$NDR,98J$+CN\E@A8>:@,2O& &WTR4
M =%<B^ZHM/J!%6J>%68)J:+[TGW_UG]?@P4$\E+#?HQ@_>C'G5X$F=8(_Y%=
MV:)D5N,;,JBV8JU)D6>,C\=:C($A.BBV/8BV=Y8/@*@N\'&'FH_=NC4L60""
MJ+@1.I:&S%/&@HD_2DY^CH[TAT&[59WH'5LW3A#BF)*H>9O_#T%Z1M@$"@\A
MGK?;VY[EA7,L$8&2U#44Q4R(;!F@[19]>0P22L-$BP]CH7F:N#V>\&F^A]6;
MS"_B,?RP#4_(:>;L_/S8VI 6 (H!(YQ\4*58(ZYI,V>'Q+0 PB1%!CF28)<\
MDI#90Z9@?WV,$S=\*C-(9\IXPA(5EW1"QNG9KM#B6HI96/%'"=/#05BM(=B1
M/F=^+P0Q WW!MAF"&9)*KN<,Y\1S^'[@"X?.1LJY." EA\W:;52IF<IE9K<U
MHJ!%0.=0I&JVV6Z=9>"!SH1 =-?:J.*$&P,Y[)$Q7N)_G&%,$*!HEZ:UG!!J
M.)4%H1&0172!. HU@\QX:EQ\&1-Z,D%)LC5,>M] P;PHM0^[SBPSL#(E(MBI
M(EKO=B_:,6039I-5*4@*[]:4)H6'2-NMF.?<"D3ZI%TK?<+IBVLR04(K]O54
M+;L -PS:0'76V3HG "$H;EJN:2.N;22AC\%@22?PNHATGO- I-T*5&RXACO.
MFOXH\@Z:@!/VG7 GB(:KD09&QG(U\U&)M 9]0:R-D$ )(FUWG\%+/26VX++B
MLH"[3T0*^[6O6D]%^G?$UG+>Y&B]>%;U0W(_29G. UL?< 3DG:"DFGGNDK::
M7V"DR7 4V$VLA)YEM]."7AR./LX;^6+2'R*O1+@<PJ[)+NAU00B,!1\BMJLA
MG(!UF0ZU35J;[-">[X(MCR )O F<GG01H&EIM67AY,D7ECF$IG@,UQCC)<MF
M3*>N+?D:Y&3?(RP"[IQ3<5!9XX.;N8A=/ *R(4KL-@%KYA'[WT[=%OE;MXOX
M)-)D%Y7U6.QA/=2=Q0+;LF[7]XKV3\Y^6^SK= N58\EV7H2]NT-5%&JZRY[1
MLR$"FM#5LZ.4(POHYY0% 0^U1-AX!8VA%OQ]=RB $S"26\::=)^M($N\0+#;
M_2=Z7"MP@61#^BT2WTG\.(_L:[1:OG#[B53LT_:PZV/4]2>D)T?(B1,JS&PA
M#+2.%;P<N2$X$7A [RZ\?[*.\POV'JX.C\Y/V?'I^?G%X<G)V:N??^KT.O;S
MY<7A<?C\]NSDZI>?.OU>[Y^=/\N!,\/>"C.TYK9_]2;L?$W.-^9I4"=>I$[Q
M_M5)6#&323$AC6Y;E>YO79T<K/^ZO[F\8,5A=0ZN*%%>4Q#.D/(P%+/EK6#'
MQYQB&#S.W%;<-I6VJ8O!*A-K.:RK]&;1T&XUJH:91.@=^M"'N.Q(16Q4IOB4
M<^G(9BKK(F6B_!.AR(NU=?6&_J.#?+2>Z#N /P? V_<'\%+]:E&SHC?PV8BF
M#M2==;!%-)5-A2R0(SIDN_K7YW6-/&ZIV(\6\KW 3[,; .*N N;(.]JMT'.2
M2-2%GIJO9AG_#^@;_%GT^<;,&@SZ;Q>1:)/OJG%3HZ*):9=KKP#U(BKJ1J2%
MA(,QE8R^JO50>J(-=7@,.ZY3?B*,-&E=H[M>:.N/A97-UC=U:%UH!R>J+%@J
M413;9:[^#A8&OLG1VX(VSU$26-R'GH-_X<X0@2+Q+XX1_P^6P)_>RQ)>KV[D
M\*&BM@=2/%,.W_F^!,' S0SLZ<.U-1 PY-E[7>9%/"<XH0RZ1IDUI^ZWTF.>
MR0\.&NW6E-"'.KZ<4K%J +.4:]O#:C;*R86[\00^QW#UDCK-W@#<.-E03XA:
MA0#8QD<0/-*\3,J4  RH7HNY\\6@:IY^A]T#PF[XI6'GSYP:Y5DL\]1EP-0(
M*N:K'!D.N8$#''XL<M</"5T6^R(J<J,R0C)U&",V5BIA(^[:\_8WC82"IZ')
M8UVB,D82]LN,7W/ >"A3W]VD7A[Y7>;[80YNMH?TKLS<T,WV<$9$>LQUDM+T
M'V\BPMC.3*.+2Z&"YG:Q$#89P6<GK[62@FSG.X8?$,/QPV.XQJ#QYVW]'/7%
MEY!#%?@T<S&[FK0 # 52V=(-+2DY<)W$I<6N^]=8.N5S"L.6NF^;UAZ;7*X?
M _BG;H_1DFVYSA^BML*/^7>D/2#2DOLA[26.Z1Z3&HN\5=,77JS*39=RW7:K
M^B*D;R&Y3<*,>J+21.@Z/Y53$*"!4DHCD#15LP!KROAL9NN7?H?- \)&W \V
M;^D$J;]OD&A733INJJ :"M?*^53W#A!MKJ6Q^++PL:F9L-/_B:()M1L[1H2\
M<MIN&9'Z>S.4T]% S5VFP OO2BU-(OV YB-Y&B65@6>*EM/<SCEFW$Z8?-:I
MK%OUVR/-+(4-D1DJBQBF4=A9U:VE) 9G;H$D\%.R0+E@)BDMM((\K51S4[AV
M@C<=6\C81"%T!$)&HF^KD7QV&"L%/1))[ VC2@35>';8:X?L<\]38W;'F:%+
M+.$+5UG:>RWT@6#YN]+OHX7+#*0@4]\EL?6B&Y02+WBW1 (]]Q'"-3K %A(I
MGTLK&@:1-1/.L7'8V16DLXF$-.(F+NTEB;D?8#KQ"SL!U6J*HPQ:@$HBMR<R
M%2W<-:G0$8$B0N0*>EK>SC=2HN;75?E;+:N>9&(,\--@A[XD_X52DP&%$#8I
MW3EMR&LOT\)4CJY_<'<0P%TH<_'K%"4*33='O$RI[H4FA($I<!IZ"J[A\]Q)
MNK@Y$O60E-D9*-F(A/CNFD7"IWQ,RI6CA8+:3P417P/))5)^8_]^B.GV%'7I
M;L:569V_DBVX2LH9"(\+NDP27J>=I*&; (@9A !GUHNK8-"ENQYD+SO1<)IT
M4 TP*SW5^E&ZJ8UOL=U[QZQP^_NL\#$=V?_4K'#P)6>%]\N&%K,,2HKVV%?-
MAE:.)#\C15K<+Q4C<+ QNG?6E&B41G/*LGE!>8#WI'8(2O<S*"V(_$71<!LR
MECHNIPBT<!@F<O'N=H+EV[L+30V;9#02+G+PF2K(R=NPGI!OG:K$77]##!:Y
M;<.&0<9BD><\+_VUR[?D>[_B3'NA;/>Y)L4Y*I[<5#N4R_Z8J$FX-@FKFD'5
MG?.??8.J>8?FW'9H'NM]F4^\KXBT8#BW^8>HKYBZ6_(VX2PFR'4;U8:]WFK_
M=,DF&NRXU)K>?",H!5F\]OV\^V^?)MM+V^MNW2_?V?8W%"C18J[>A 6ZG/5C
MU$*M*ZO)B".K!>4_E% B'5-WW%MW=_C\DOHM?W5K)#7*H_I.^41P6S[X^<PY
MW2-DOY*;T>$";QC K[QLO\G.,C:6UZ[.EB:<@RW[$V4=!T^FTKN5F>M$D<YD
MYIP2S8+&MA08A6N(2.^5$=612A/2]L0[N4M71/F_#ZB,8>E^O)-0EZDP;B4I
M1HMQF2Y,3MNMQLG9]H E\@4-Y).BH$_78I6F/#?(N<)O>ZP1(#LV;[HCJKGH
MUPGIU:U M4-[[+]\_>JJ*6W7R _"B5Q+08L.O%M?N]G](_;'R/XF  Z4%JAO
M* ::J,F!#2N?*OKGR_E0LMTF]8T+M&6VV(G21LR;E^_?3F21";IJ?[%:UD9>
M\!@C4N?@U>75UN';TZW#?_WZC07.^U64@SWV.K=><1?9 6K]KUM@?K%J;XU*
MEA2_17^![?XDF_YR^[]02P,$%     @ *8L*5>6'"ZVO#   %2D  !8   !T
M;3(R,C(S,#1D,U]E>#DY+3$N:'1MW5I;4QLY%GYWE?^#EH<$JFQSF\D,EZ7&
M@'.I(4 !R6R>MN1NV5;HECJ2&N/\^OW.47?3!I*9J652J>0AMG4[]W.^(['_
M^NKMR4&WL_]Z-#S&IZ!_^U=OKDY&!_OK\1.SZ]7T_N'9\0=Q>?7A9/3OE8DU
M85=L;A1!7.E<>7&JYN+"YM+TXD!/7"JG)RO8B*WG?W??GLBEFVJS*VCI!O^_
M_<N+P=;/1=@3B<VLVQ47*ETY>&;&OMC;7S]_&DI[(JC;T)>9GF+(Z>DLK!SL
M'QZ,;F=ZK(/8V1EL[J\?'OQ#!!-E@G)?EHK7:I,JHK4!=6BS)YY4U#=O7XG+
MBR.0RK?P;WOCIW3[O^IV9Z>_J?/IQL;FX&,Q71'#DZM_K_S#VO\S93PI$=AX
MN BE.-3V?"9=+L70&%N:!.>>2'S.A)V(\W*<Z42<328XV$R?U!.>7-#X/WE(
M6^"/I0]ZLJ@&&U_2)OKYZ:N3T1]G9\>];N?HK">&Y13K(V._]L36QM:6(*G[
M8EE;O;CDC4D&8C7,E'B6I9]*NW=D\T*:Q3/'OX1U]01MKT;7Q.JI]*G\M"N&
M'Z[>K?6$% 6?FJ@RZ$1FW4X2SX&O)Z57J;!&I.I&9;: &80T*9)"GBN7:(CY
MF<:,Q;0 *TX6? RT%&PJ%U@=#9O2K,@:XTHC2JC#S9T.01E11&/;RMCXTNUX
M\ 4#8+4.GFF"$Q]L<@W9>D(;D6E5TOS27+!P-!<DYK6Y41AT'M1E$!XS,VN]
MZHG"J?Z$.$C%7#HG#2A@8U&Z9":]$@WM;N<^\1ZK0":5FHC;1X]XP'2T%:P0
M]FJGCK_6!F*8920(K? J*:$5#?(0@4;JU=W.7&/=&&MLEHKQ@AUC(*Y::X3V
MPI?CCRH)Q V<]%H%YMB2?<"127&X-3[*08-*)+ 'CC562.]+R)(H?*,#YC/%
M^^!-^,K\=#L-L1PFQCY21:8"^8JK]A'?,@FES(37GQ5-(/9S7TM9'S'X@6*:
M[% %(=P&N<ZDK M$$<ML8(G"V40IC$^<S9<T@7B#\M(;*)]^T505=CE(U&%0
MZ$)EVI!YO J>PB#)RO3Q_><7H_<C$[J=*X=8%>I&9J4,-#N\V-S8Y!VT+C@E
M0TWE1OJDS*03HUFFG.\?2Y-9+RX7)@7+2JR^'QU?(G'0YJFS\S"K;9K4"<A3
MJO&M-"'&I0?3WB/5D=?1WKEUU\1*(@L=L(3&I\H@AV38Z0KK9% 43@4BUG_W
M?E(!A#]WE7Y<NG)PA)1!)H/<^$H)Q:7=SBME2AV0.1T'$*=<S^K]:.%38FSM
MM2L-].0;^_VHP?0P\>4R12XQV8*R7ZZDX80B*:Q\@9Q74O8KD(S8FQ\DZM8R
MZ"[G(>E"/,//5#813DVU#_ ]S8D;/A@#PXB7V!&U<MG?[G967^I,B5,[B&/;
MV]O]K9]W?GVQM1:KS1QF2U6"2$)>5) $QKQ1Q#>9[/(NRQ.7HUL4#3/E_)%K
M[XEXJUY<CHZJ4D&,G"7!CI6+=']!2 $J; ZPM="J2;!?UDA,S8]KQ:DL)@BD
M+5J;*I\XH'%.*"@M]S._'5.A56F/JP."^T;J3(XSE%@(BF(3*A^NG/VE#I^G
M%.)IY/Z9S(L]<#X _"$@0%K?%?LOSTZOV@[7IQH2O8[B)B:,MUS;X&\_[>R(
M<_P0PQL$CX)"?D)2>IE9@@GDGA^0:O#M PX J-I?I^,/>E23P*3*P;*0H:6&
MWQ+F=@ =T:*OL_- SAC)H@KD;N?DY&A).LJD0%I(;L>*O(\,TT.W(UZC+Q"7
M2,8*OR^Q644E;6YM;/3$H06,0)"]'0J8>W/C/ON56&TIIA,2@0&"1]E. >B(
MF&?KR0QXJ&5"SB83$"<78Q<='3WW8J[&'IR(S!++*5&:A5#LKJ_/Y_,!P,I@
M:F]^K,0#/P<^]!P-2D;-@9ZQ@2R-C:&$0@"9&*Y2J'A%^"TF8V SG<!!.8%$
MJ-NL&Y<$B1=?P7AL+,< %$<2R;&*6V0&1F)P^_LHD1=0KB(F/F+"P\.8 4S.
M9QJ@VY>,O".5'A]'BY>XG=N2<*4"-L_D?%)FT(.VS'D[+8(-)SX!VND)^3'M
M9#!_'[[BC)B>B3LB_RB+W[WOM"O[@R).O>S8EN'+/=H/UK@NRPF<ZQ^TD#40
M%'.-/(Q9Z\($?F;K7JT"A11DJ"X%>U"[>ZR:3..1KIR8*9GA'"2VM$Q"U;=(
MQIX5T&TV=CL-/FYUKPQO::E#+4;OIU(M@]-)'Q0 R5/MD:^!IV(G53'_W"_S
M5Y.O +<2P_2S,@LO_G/1/SN^>H8 V1.K*&=HF"20A5KK=J \13UFOTHD<'U$
M]8(H4GLP=56MI8*)DU<]DN_+$G%_[N[J[AM#4(7#K(WV#^TMI/MC>''ZYO35
M6D21%F"ER.0R2SD:N$4&MHQ.$7[?EJU'.PQ9UT(D5C6A]"-FBP)6)(1$V+>V
MB%@='K\^IDL*JD-@ )^_2P?Z,HO2C2[$:L(C]I:U#N^&3!"3W$0\D'1Y[2K*
MO$:Z;PSF2]1.XV/BC$4ZY6Z6V!>&W-$")4%;"C&4/.BFSVVVZ+_7?6 /%QFD
M471?2X,]$>:V:II))](MQ"0KK=.IZH_!)MJ )=^#4HC#V@<%.;B/J$,;[J%L
M3DIA3DC#]6E,OMK-A>)&(J%7Z+?,J@UD)&TF?(/!D3?36>H(SG$ -X=%8RF3
M+ 8QW5'L,XHHL8$[E78T-KUJKRI!5>3XJOM<5>:SA.Y1"PQ?1)W_?O1LC.C9
MPTJ^ F:^R$GNVN#_HV4="/I@ICD3<+=)?,+=V#G"HJ#TQ9$@I\92^H#.6!TS
M:V$5&*7,.#@P/B.XEELX5,H-&V<EC_S)9=$$G.-G2'V*P!5JI?(%)>.F_V6=
MQ/L7XL; )4H'M=-&6<#6-^1\M9S(3E%M,^F)D41IFC]SR+U&'+MR2F =U&-!
M;JX7W@TN!VA=;,J$>=TPA3O<-3EU3S JG2W04HFW2) )N]AP^HBUH00E';1"
MC1E+_;5+"QIZK:BNS(* \IR\T19Y1<21H5A]]WZX)A"F%G,))7M$*78%Y?AV
M4E*RH XCWN;I*7.-53FQB4\0U(FJG+6PG%OH/@%-3PU/*I"UY#0>?%(Y2/4$
M]@)G_6#[,= A8:&A'8O 1& HQBG?\Q7$RAW"^%>_CRY+9>DN>J*IVL/Z3R6L
M2/V*Z/>KQZ?]XS?O:YKQ)$A?8,D6/?I4(V,;@LUWQ0L:&W-&;L8.,YE<B\TB
M,()L/0[AX$=HC*'7Z_Y8P?'!2,&,M>F^>(0L\0+!SI?Y9(G;"EPBV9)^G<2/
M$G^/)OMKV/)23A ^*%I(&)?-9<2[&FUW.^=.WQ"H;MTGG.@Z2,0%*3P7PX0]
M?G-GY^<?#(T^UJQ5==%7=R?0P%RZM)]9R_>-S9V.C_.,4JL$03=*\?DA]C*D
M_5G4/N5C[>L"VV36K^J_VWEH@ &0$V(F)RSB20\+6_+]NR:Q(&;=X#5L4I=_
M7X@YHM''IDK6@A*8233E2]^K1(L?8U1A)+MZ%*$2OY"B-%V8+*VF')L_/$3=
MTJW"O<'JDGMY,)>+>P.4Z9>'@%+- WY@1^H)[QT'Q7]\2!F5%;WJ\AB U%3=
M7T@WA_5(A1V,(O/<*-%TT_PT$8M9?";Q.M<$*&@">#&STP55T2]Y4BPP]UVQ
M!CP] *10U7BJ>[F.L++7/@' $&=S3>4+NL:8P&, ,RVO;.[@ZL(=38.%:'C:
M]W]?>&@8\",%2G!U0;%TYMWS$?BP=Y!W G!N'=PUI\8.NR)\(:'&:@$8S!CA
M>42ESF:MGJ#'$48],HM>M0S5RU0;04^DSDK'9D'OAAH 8(QPKJ2_6]D([K2_
MKCEKO7'EU&!@A)H[!$Z8U?7_[]\25Q9,Z3TGDGS\>KCFZ.Z*#3OK1PQ^JG,*
M&J8Z'"&?-@/Q 9$O^?6MI..PCOR#WA!17.D2)BV)8*;Y/8Z1&O3QY7P6;\>K
M9\'G]-.@!,;KQ9:Y9&R+@3(9&35M7!M^UM>XQ W:,[K<C<@5BI'7O!OATC@;
M-9:]UAT/ZT1'ABKTV%RAT0MC'N^T[#BK*Q6_G-(;,*ASJDU)]";C.E$61,3'
MB^D'"1&M6Z.&7O-H*1GJ,V8G3@UJD&ZWK9,RD+^U$"N38B^::WHGCFE&)-K!
MKB#!?Z,0K^I[B+M$%230W0Y"YI]*[:+-,SG_'D%CA%P;CT NAE8"N.,HWFCO
MMN'"$TE!U_;B[%H_H6*.9EI-@/L,M2& _F>$Z)5[0@HYO.PW"3\>:TMWZD^L
MDV^/+2_H!2D QI?Y$ZKI9!%F,J?'F$ /E$]X\AB,_I;Q\45U^O=OA[_6EFWM
MB3.^Y_&[XD3Z\(V[M&_7,JW3GS7&OW.D/X?\'U!+ P04    "  IBPI591#^
MV.(-  #N+   %@   '1M,C(R,C,P-&0S7V5X.3DM,BYH=&W=6EMOVS@6?C?@
M_\ -%FT*R([CM)W)98)Q;FTQ:1,D:6?[M* EVF8CB2I)Q7%__7[G4%+D7#J=
M1;;H=AXF#47RW,_YSF%V7E^\/=[M=G9>'XX.\%/0?SL7;RZ.#W=WUL)/?%VK
M/N_LG1Q\%.<7'X\/?UN9F-QOB?5!X<6%SI03[]1<G)E,YE%8B,2YLGJR@H,X
M>OIWSVV+3-JISK<$;1WP_S=^>=D?OBC\MHA-:NR6.%/)RNZ3?.R*[9VUT\>A
MM"V\NO8]F>HIEJR>SOS*[L[>[N'U3(^U%YN;_>'.VM[N_XA@K'*O['>2ZLW;
M5^+\;/^W%9\-\=_&X'FR\6]UO;G9&^IL.ABL]S\5TQ4Q.K[X;>5_S-)WD;LF
M G..%KX4>]J<SJ3-I!CEN2GS&/>>6AWK?"K,1)R6XU3'XF0RP<WY]%&M_NB2
MAO_K?%GB3Z7S>K*H%G6>*+H<VX)/OWMU?/CGR<E!U.WLGT1B5$ZQ/S"V&8GA
M8#@4)'5/+*LK"EO>Y'%?K/J9$D\^E\9O[YNLD/DB_"*,K9;I;/C7,['Z3KI$
M?MX2HX\7[Y]%0HJ";XQ5Z74LTVXG#I>(B8E+IQ)A<I&H*Y6:@JPB\P3!GV7*
MQAHB?J&UW."S !M6%GP--.1-(A?8':R:T%=1W%A6>R=**,/.K?9>Y:((IC:5
MJ;L=;%K5SX*<P_7HQ>!%].OZ<^' +4Q274&<@#_G37P9$6^1T+E(M2II1_LK
M&(+W62_Q7>=7"HO6@2OIA<.7F7$J H.J-R&V$C&7ULK<NVX'!XO2QC/IE%B/
M?GDQB :#P5_Q =YKYF5<:91$KZ^]934Z_&?UJ;94F^YP(QJ^8 5T.P]3;E]:
MQTQU6U]<X-/-T>5C\)1[1'_&@M"52R($=KN=FE\QUVDJQDIHYTH<=ZJ05GJ5
M+L2X]"*6.5R(?E&-/+C53!4Y#)G+S[1K8CPP"G)CG6/?+;=@%U)P32N4C&=!
M(/:5)8&([WMXKE4,3L4_!_WG&U$C84/P(4IW]7.'"D+X7C)#1/)\IG&)^ES*
MU(58N%>P AIAF<A&%5_?+%8D4N7X]FX'=%$]6O>I:XI8IRI"N/X!L8(!Y'1J
MU116%%-K<&EA3:Q4XL3$FHPYJPTFPNV%BCW;E>PL"^R_UAE[ 9A9'X@,3J(-
M,NA80:<**24I8T_GZ;(F%=!"HEV,K '/JI,-/ MGP^^(7+ZX92JBGCLX=B$7
M<IPJ,5YPONR+$3RSTJ13<4D$%$*:G:XE0NW!SJ3)S>&+]A;8LBUDG")A4&IL
M9^SU]9"R(^'*\2?LI9U,6WKM)A+RX@0Y*XZ@GECHABZB^V.3)YJ^N_Y/5.)(
MA5510J0CSR<AH:*PL&)RY;_F6A1],KF2>5P[2E6),I"H,V"A"Y4B=H5T3GE'
M%2!.R^3^\Z=GAQ\.<?;":JIUZDJFI62O&YVM(V#H!.WS5DE?4[F2+BY3:<7A
M+%76]0YD#JN)\T6>@&4E5C\<'IRCEM)AA,O<SUKARP79.J3A;=>JG,B-L#OB
ME7-0MT-GY\9>LB_(0GML(7>?JAQE-<5)6QA*JY1$"SC?C^\G:!6^S55Z8>O*
M[C[R#YD,<N.?E.HL5/-*Y:7V"TXT,N0,&9+H)P.G$F-C+FV90T^NL5]33GYT
M)?W-8#II\%&=LS*9J*K +D2F9,[U75)8.<I7I4,V*HI4L3??*2&M;=!=QDO2
M^G"'FZET(E (M//P/<V5"#X8 B,71S@1M'+>V^AV5H\TDN\[TP]K&QL;O>&+
MS5]?#I\%H#6'V1(5(Y*01!4D@3&O.%N3R<Z;!,U<'EX#*N13SA]5 6CCF_/#
M_1HHX<-)[,U8V4#W%X!II.%UI'^J;ZF&5,BU#V@$&T("0%HBNHERL46C624,
MM"N9J\/YIF! D@F$1=74B'9F_W#_=CWX-3 R#*5D B[2;V#BWLITEU@?BBFT
M:GA[V-X,"!XR^E?%;^$R^!E#.#,F"*T2@C2 [?)*ZI1J;D1F1!'S5816H7RD
M_9<I); DJ.2)S(IM DI]-#L$_,FIML3.T<F[BW8\]9S^HD)045H(^?"MM)><
MX9]O;HI3_")&5\@-H/T<>CE*C;$1!]]')%+\ZR/.0_T[:W3[;D0-$9A4&5@6
MTK>T\'O,W/:A(H!)^Q?LW!$T)"I1YZGCX_TEX:A.H+5"ZCX@:,QE)1(0X;6>
MSL0Y2HW"[^<XJRH<,1P,X#I[!B@!.>3M2,";@:%N\5_)U19C.B$9V-]081-T
M<$3,L?& /$W;@IPK)R!.;ELYU5.@>35VX$2DAEA&^@6EF??%UMK:?#[O T;U
MI^;JY\JKF@ N86=$@T)_TNTD!O1RX\G2..A+:(0:&8H&"A6G"%F&6@/4B+[6
MRQK=M?>-2VJ"%RWT*6Z!3S:6Y=X,5Q)) M!T1*:AM?%LS.4;> .E8F+B$SXX
MN!@S@(^AV7!E/&LP<L37T>8E;N>F),1+ #R5\TE)^4D;YKR=]3DHJ'?1$W)D
M.LF(_1:P%K@C5!_BCLC?R^(/[#LK-_.E?_1ZR%XJ3;:0:J9J&_L_ERJ/*0V(
M7J^:UNX<O/E0TPPW];PIL&5(4])J96P\X/Z6>$EK8Z0*99NUO52BLULO/!NF
M-4W%Q??0& .77O9"#[6%2DV,M>F^O(<L\0+!3I?Y9(G;"EPBV9)^C<0/$O^(
M)KN+->_ 2IHVCDWI'QZB_623Q64YT>^Z.W.^NC4)F )?C?43>*"IIT-5FT)Y
M$8"@X*!OC_BJYCQW*#%6S)1,/8T3#+7UH:G!K=0-54BJ.=CM-!U;:\3(#1=M
MM4"'D2A4HJ6W.NZ! IK$1#N.&]?,AXCYIVZ9OYI\U0(J,4J^J'SAQ+_.>B<'
M%T^0T[;%*B#(3'D)5*B>H06\IK94);TJ]R-;(1$OB")UK%-;P2,".32W<RB8
M1R52]:F]@4IO<@+/G!G;_>>>N89T?X[.WKUY]RJ,T_8-X'.1RF66,N5GBQ1L
MY3I!QOR^;-W;\\H:OZ 6J@E5##%;%+ B879".;5%Q.KHX/4!39().X !_/Q#
MVC&AW2#=X9E8C7G%7+/6X=V0"6*2FX@[DB[O704TTZC0C<%<Z6C<$VI= %8\
MDF'V14[N: !LH2V%&(I;DY7@E:<F7?0^Z![PH@T,TNJ%U4N+D?!SPWX6D#0U
M$).T-%8GJC>F&2;\N.U[4 IQ6/N@( =W 2CJ/$QX:,3(QN B6=_&Y*O37-NO
M)&IPU8^5:76 C*3SB6S&8C.=)A8(G.*WVVDN"\9"G5KT0[JCV&?D5^( ]\[M
M:&RF)_6(LHH<5\U#5E7^14+W*-\YOQ:<_K'_9(SHV<9.?H]COMISF3#+^"^'
M*'U!/YAIS@0\_R ^X6[L''Y14/KB2)#3W%#Z 'U6Q\R8!+C%E:GG%AGK,X+8
MF8%#)3Q"X*SDD#\9R>0>][@94I\B0 QXHUQ!R9CV\42&=>(9H!$W.5RBM% [
M'>0IYQ4Y7RTGLE-0VTP2EHP5VEOXR8E%[LW%@2VGU%^!>L!0S<#K??^\CV8:
MW!-AWC=*X XW;7<]ISXLK2G0Y(NW2) QN]AH>H^UH04E+;12/=DT4[!NYYXQ
M&BV]5E179EY >U9>:8.\(L+*2*R^_S!Z)A"F!M]B2O:(4IQ"=\Q/2)*2A>+7
M%WI:T5/F&KLR8A,_09#&SEQL"L.IA>9O4&%:(\H*%R\YC0.?5 X2/8&]P!E0
M3B\$.B0L-+1C+(T6>9;P_S \_2N@<BXGL 4R(+SOO)FUO*_1=K=S:O45@>K6
MN.18UQH79X0,,S&*67WKFYLO?C)H<U^S5B595XV&H(&YM$DO-8;'J<W(JGI:
M8R^LO(T&9M639!C40_NSH'T*;NWJ;-V$Z5?UW^W<-4 ?91C@/J/"YD@/"U/R
MJY@FL2!FW> U;%*7?UN(.8JM"TV5K 6ERAAK"CX75:*%'V.D=$1.O0I,'_Y!
MBM(T,%G:7;^HW+HD/'?<6JR&^,N+F5S<6J"TL;P$R)/?X0=VI)[PUG50_*>[
ME)&FT:LNKZ$J3]7MC30RJU>J0I334Q:-&IMNFL=ZR#](C8;?(9W.-%4G^@#P
MD9KI@E+R0Y[4O%LNN6)=/2-^^0P%@Y)HI@-&B=HWT/N:39J4?&/,1-2/0K?'
MCG45:%ZB2K<T 'S@':7/;S#(Y]6 8NE.[>K7*GZ9:? 3/5<9"W?-J$O J5 +
M2:BQ6@!3<<%Y&B".-6D+8$8<8=1PL>@5_LQX>K<$QR92IV5X[&R>Q&KA.:RK
MG8W@5KO+FC-Q8[R,T"I6J%- X/A974S^_A"\LF!2W[ \!KF9?M<<W<S8<+)^
MH^%'1*N@81H8!/R@\[[XB,@G!<:RI/NPC_R#'OI3-&8T4RF)8JHE'3-AS/-P
M.NMV>/A?/5@^I3%?CEX]S!=;YI*AQP)DX3+;] 1M+%//<8D;8'T:[@88!,7(
MRW!:-KY&34K4&O$$W*<=OT944*09H4E'/2++8L9I7:GXSQOH#3Q=A%2;D.A-
MQK6B+(B*"X/IKZF!1]'L!V 0W6Y @,1JCAJDVSW0I/2E78(_3(J]:*[I3T!"
MFA&QMK K:/"?)(67B AQ%ZO"LQ[J$^#Y<ZEM,'DJYS\B  FCH<$]HR$> 0G
MCOTPT-YJHX5'DH*F]N+D4C^B8O9G6DW$$;JIG(<4)X0.E7U$"AF<['<)-QYK
M0R/U1];)]X>69_0^YL5>6F:/J*;CA9_)C-YB/#V_/N+-8S#Z>\K7%]7M/[X=
MOFU\/-P6)SPS<%OB&,WU=YXF?[_1[AK]O7+X V;Z.^?_ %!+ 0(4 Q0    (
M "F+"E6P/7#L/0,  /(+   1              "  0    !A>71U+3(P,C(P
M.# X+GAS9%!+ 0(4 Q0    ( "F+"E5MA[#=_PH  &R'   5
M  "  6P#  !A>71U+3(P,C(P.# X7VQA8BYX;6Q02P$"% ,4    "  IBPI5
MYV8GT5('  "_6   %0              @ &>#@  87ET=2TR,#(R,#@P.%]P
M<F4N>&UL4$L! A0#%     @ *8L*5<RE'\56&   "X8  !(
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M 0!T;3(R,C(S,#1D,U]E>#DY+3(N:'1M4$L%!@     *  H F0(   R- 0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
